<?xml version="1.0" encoding="utf-8"?>
<!-- Copyright ©2016 LexisNexis Univentio, The Netherlands. -->
<lexisnexis-patent-document schema-version="1.13" date-produced="20160512" file="EP1020191B1.xml" produced-by="LexisNexis-Univentio" lang="eng" date-inserted="20081224" time-inserted="125804" date-changed="20160511" time-changed="102138">
  <bibliographic-data lang="eng">
    <publication-reference publ-type="Grant" publ-desc="Granted patent">
      <document-id id="83049814">
        <country>EP</country>
        <doc-number>1020191</doc-number>
        <kind>B1</kind>
        <date>20081224</date>
      </document-id>
    </publication-reference>
    <application-reference>
      <document-id id="1630822">
        <country>EP</country>
        <doc-number>99302556</doc-number>
        <kind>A</kind>
        <date>19990331</date>
      </document-id>
    </application-reference>
    <language-of-filing>eng</language-of-filing>
    <language-of-publication>eng</language-of-publication>
    <priority-claims date-changed="20151027">
      <priority-claim sequence="1" kind="national">
        <country>IN</country>
        <doc-number>EL67D1999</doc-number>
        <date>19990112</date>
      </priority-claim>
      <priority-claim sequence="1" data-format="docdb">
        <country>IN</country>
        <doc-number>67DE1999</doc-number>
        <date>19990112</date>
        <priority-active-indicator>true</priority-active-indicator>
      </priority-claim>
      <priority-claim sequence="1" data-format="original">
        <doc-number>DE 6799</doc-number>
      </priority-claim>
      <priority-claim sequence="1" data-format="epodoc">
        <doc-number>IN1999DE06719</doc-number>
      </priority-claim>
    </priority-claims>
    <dates-of-public-availability date-changed="20100612">
      <gazette-reference>
        <date>20081224</date>
      </gazette-reference>
      <unexamined-printed-without-grant>
        <date>20000719</date>
      </unexamined-printed-without-grant>
      <printed-with-grant>
        <date>20081224</date>
      </printed-with-grant>
      <publication-of-grant-date>
        <date>20081224</date>
      </publication-of-grant-date>
      <intention-to-grant-date>
        <date>20080516</date>
      </intention-to-grant-date>
    </dates-of-public-availability>
    <dates-rights-effective date-changed="20100612">
      <request-for-examination>
        <date>20010112</date>
      </request-for-examination>
      <first-examination-report-despatched>
        <date>20010926</date>
      </first-examination-report-despatched>
    </dates-rights-effective>
    <classifications-ipcr date-changed="20151027">
      <classification-ipcr sequence="1">
        <text>A61K  31/57        20060101AFI20080303BHEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>A</section>
        <class>61</class>
        <subclass>K</subclass>
        <main-group>31</main-group>
        <subgroup>57</subgroup>
        <symbol-position>F</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20080303</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="2">
        <text>A61P   3/06        20060101ALI20080303BHEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>A</section>
        <class>61</class>
        <subclass>P</subclass>
        <main-group>3</main-group>
        <subgroup>06</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20080303</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="3">
        <text>A61P   3/10        20060101ALI20080303BHEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>A</section>
        <class>61</class>
        <subclass>P</subclass>
        <main-group>3</main-group>
        <subgroup>10</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20080303</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="4">
        <text>C07J   7/00        20060101ALI20080303BHEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>07</class>
        <subclass>J</subclass>
        <main-group>7</main-group>
        <subgroup>00</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20080303</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="5">
        <text>C07J  13/00        20060101ALI20080303BHEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>07</class>
        <subclass>J</subclass>
        <main-group>13</main-group>
        <subgroup>00</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20080303</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-ipcr>
    </classifications-ipcr>
    <classifications-cpc date-changed="20151027">
      <classification-cpc sequence="1">
        <text>A61K  31/573       20130101 FI20130101BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>A</section>
        <class>61</class>
        <subclass>K</subclass>
        <main-group>31</main-group>
        <subgroup>573</subgroup>
        <symbol-position>F</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20130101</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
      <classification-cpc sequence="2">
        <text>C07J  13/005       20130101 LI20130101BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>J</subclass>
        <main-group>13</main-group>
        <subgroup>005</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20130101</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
      <classification-cpc sequence="3">
        <text>C07J  13/007       20130101 LI20130101BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>J</subclass>
        <main-group>13</main-group>
        <subgroup>007</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20130101</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
    </classifications-cpc>
    <classifications-ecla date-changed="20151027">
      <classification-ecla sequence="1" classification-scheme="EC" country="EP">
        <text>A61K 31/573</text>
        <section>A</section>
        <class>61</class>
        <subclass>K</subclass>
        <main-group>31</main-group>
        <subgroup>573</subgroup>
      </classification-ecla>
      <classification-ecla sequence="2" classification-scheme="EC" country="EP">
        <text>C07J 13/00C</text>
        <section>C</section>
        <class>07</class>
        <subclass>J</subclass>
        <main-group>13</main-group>
        <subgroup>00</subgroup>
        <additional-subgroups>
          <additional-subgroup sequence="1">C  </additional-subgroup>
        </additional-subgroups>
      </classification-ecla>
      <classification-ecla sequence="3" classification-scheme="EC" country="EP">
        <text>C07J 13/00D</text>
        <section>C</section>
        <class>07</class>
        <subclass>J</subclass>
        <main-group>13</main-group>
        <subgroup>00</subgroup>
        <additional-subgroups>
          <additional-subgroup sequence="1">D  </additional-subgroup>
        </additional-subgroups>
      </classification-ecla>
    </classifications-ecla>
    <number-of-claims calculated="yes">7</number-of-claims>
    <invention-title id="title_ger" date-changed="20081224" lang="ger" format="original">Blutzuckersenkende und Lipidsenkende Medikamente</invention-title>
    <invention-title id="title_eng" date-changed="20081224" lang="eng" format="original">Medicaments for hyperlipidemic and hyperglycemic conditions</invention-title>
    <invention-title id="title_fre" date-changed="20081224" lang="fre" format="original">Médicaments hypolipidémiants et hypoglycémiants</invention-title>
    <references-cited date-changed="20081224">
      <patent-citations name="patcit" date-changed="20081224" />
      <non-patent-citations name="nplcit" date-changed="20081224" />
      <citation>
        <patcit num="1" dnum="EP-A- 0 447 706">
          <document-id>
            <country>EP</country>
            <doc-number>447706</doc-number>
            <kind>A1</kind>
            <date>19910925</date>
          </document-id>
          <application-date>
            <date>19900322</date>
          </application-date>
        </patcit>
      </citation>
      <citation>
        <patcit num="2" dnum="DE-B- 1 301 999">
          <document-id>
            <country>DE</country>
            <doc-number>1301999</doc-number>
            <kind>B</kind>
            <date>19690925</date>
          </document-id>
          <application-date>
            <date>19650129</date>
          </application-date>
        </patcit>
      </citation>
      <citation>
        <patcit num="3" dnum="US-A- 2 752 370">
          <document-id>
            <country>US</country>
            <doc-number>2752370</doc-number>
            <kind>A</kind>
            <date>19560626</date>
          </document-id>
          <application-date>
            <date>19501226</date>
          </application-date>
        </patcit>
      </citation>
      <citation>
        <patcit num="4" dnum="US-A- 3 475 464">
          <document-id>
            <country>US</country>
            <doc-number>3475464</doc-number>
            <kind>A</kind>
            <date>19691028</date>
          </document-id>
          <application-date>
            <date>19661107</date>
          </application-date>
        </patcit>
      </citation>
      <citation>
        <nplcit num="1">
          <text>BEG M ET AL: "A study of effect of #guggulsterone# on hyperlipidemia of secondary glomerulopathy." INDIAN J PHYSIOL PHARMACOL, JUL 1996, 40 (3) P237-40, XP002118411 INDIA</text>
          <scopus-url>http://www.scopus.com/record/display.url?eid=2-s2.0-0029949092&amp;origin=inward</scopus-url>
        </nplcit>
      </citation>
      <citation>
        <nplcit num="2">
          <text>DATABASE MEDLINE [Online] Dialog AN:2603885 MEDLINE AN= 79088643, XP002118423 &amp; KUPPURAJAN ET AL.: "Effect of guggulu (Commiphora mukul-Engl.) on serum lipids in obese, hypercholesterolemic and hyperlipemic cases" J. ASSOC. PHYSICIANS INDIA, vol. 26, no. 5, May 1978 (1978-05), pages 367-373,</text>
          <scopus-url>http://www.scopus.com/record/display.url?eid=2-s2.0-0017962638&amp;origin=inward</scopus-url>
        </nplcit>
      </citation>
      <citation>
        <nplcit num="3">
          <text>SINGH K. ET AL: "#Guggulsterone#, a potent hypolipidaemic, prevents oxidation of low density lipoprotein" PHYTOTHERAPY RESEARCH_(_PHYTOTHER. RES._), 11/4 (291-294), XP002118412 United Kingdom</text>
          <scopus-url>http://www.scopus.com/record/display.url?eid=2-s2.0-0030966186&amp;origin=inward</scopus-url>
        </nplcit>
      </citation>
      <citation>
        <nplcit num="4">
          <text>SINGH RB ET AL: "Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia." CARDIOVASC DRUGS THER, AUG 1994, 8 (4) P659-64, XP002118413 UNITED STATES</text>
          <scopus-url>http://www.scopus.com/record/display.url?eid=2-s2.0-0028073940&amp;origin=inward</scopus-url>
        </nplcit>
      </citation>
      <citation>
        <nplcit num="5">
          <text>CHEMICAL ABSTRACTS, vol. 129, no. 8, 24 August 1998 (1998-08-24) Columbus, Ohio, US; abstract no. 090097, GAUR, S. P. S. ET AL: "Gugulipid, a new hypolipidemic agent, in patients of acute ischemic stroke: effect on clinical outcome, platelet function and serum lipids" XP002118420 &amp; ASIA PAC. J. PHARMACOL., 1997, 12, 65-69,</text>
        </nplcit>
      </citation>
      <citation>
        <nplcit num="6">
          <text>MESTER L ET AL: "Inhibition of platelet aggregation by "guggulu" steroids." PLANTA MED, DEC 1979, 37 (4) P367-9, XP002118414 GERMANY, WEST</text>
          <scopus-url>http://www.scopus.com/record/display.url?eid=2-s2.0-0018629552&amp;origin=inward</scopus-url>
        </nplcit>
      </citation>
      <citation>
        <nplcit num="7">
          <text>CHANDER R. ET AL: "Lipid lowering activity of #guggulsterone# from Commiphora mukul in hyperlipaemic rats" PHYTOTHERAPY RESEARCH_(_PHYTOTHER. RES._), 10/6 (508-511), XP002118415 United Kingdom</text>
          <scopus-url>http://www.scopus.com/record/display.url?eid=2-s2.0-0029841455&amp;origin=inward</scopus-url>
        </nplcit>
      </citation>
      <citation>
        <nplcit num="8">
          <text>KAPOOR N K ET AL: "PROTECTION BY #GUGGULSTERONE# A HYPOLIPIDEMIC DRUG AGAINST BIOCHEMICAL CHANGES IN ISCHEMIC HEART MEMBRANE INDUCED BY ISOPROTERENOL" SYMPOSIUM ON THE PHARMACOLOGIC MECHANISMS AND HEART DISEASE HELD AT THE XIIITH CONGRESS OF THE INTERNATIONAL SOCIETY FOR HEART RESEARCH AND THE ELEVENTH ANNUAL MEETING OF THE INTERNATIONAL SOCIETY FOR HEART RESEARCH (AMERICAN SECTION), ANN ARBOR, MIC, XP002118416</text>
        </nplcit>
      </citation>
      <citation>
        <nplcit num="9">
          <text>MOGHE, V. V._DALVI, S. S._JOSHI, M. V._KSHIRSAGAR, N. A._GUPTA, K. C.: "EFFECT OF PRE-TREATMENT AND CONCOMITANT ADMINISTRATION OF GUGULIPID ON ABSORPTION OF ORAL DIGOXIN" INDIAN J. HOSP. PHARM., September 1994 (1994-09) - October 1994 (1994-10), pages 172-174, XP002118417</text>
        </nplcit>
      </citation>
      <citation>
        <nplcit num="10">
          <text>CHEMICAL ABSTRACTS, vol. 75, no. 13, 27 September 1971 (1971-09-27) Columbus, Ohio, US; abstract no. 088824, NAMBARA, TOSHIO ET AL: "Cardiotonic steroid analogs. X. Reactions of 5.alpha.,14.beta.-pregn-16-en-20-one with nucleophiles" XP002118421 &amp; CHEM. PHARM. BULL., 1971, 19, 1137-43,</text>
        </nplcit>
      </citation>
      <citation>
        <nplcit num="11">
          <text>CHEMICAL ABSTRACTS, vol. 98, no. 23, 6 June 1983 (1983-06-06) Columbus, Ohio, US; abstract no. 194935, BAJAJ, ASHOK G. ET AL: "Chemisry of ayurvedic crude drugs. V. Guggulu (resin from Commiphora mukul). 5. Some new steroidal components and stereochemistry of guggulsterol-I at C-20 and C-22" XP002118422 &amp; TETRAHEDRON, 1982, 38, 2949-54,</text>
        </nplcit>
      </citation>
      <citation>
        <nplcit num="12">
          <text>ARYA: "Gugulipid" DRUGS FUTURE, vol. 13, 1988, pages 618-619, XP002118418</text>
          <scopus-url>http://www.scopus.com/record/display.url?eid=2-s2.0-0023814455&amp;origin=inward</scopus-url>
        </nplcit>
      </citation>
      <citation>
        <nplcit num="13">
          <text>BECK: "Effect of progestins on glucose and lipid metabolism" ANN. NEW YORK ACAD. SCI., vol. 286, 1977, pages 434-445, XP002118419</text>
          <scopus-url>http://www.scopus.com/record/display.url?eid=2-s2.0-0017620257&amp;origin=inward</scopus-url>
        </nplcit>
      </citation>
    </references-cited>
    <parties date-changed="20081224">
      <applicants>
        <applicant sequence="1" app-type="applicant">
          <addressbook lang="eng">
            <orgname>Council of Scientific and Industrial Research</orgname>
            <address>
              <address-1>Rafi Marg</address-1>
              <city>New Delhi 110 001</city>
              <country>IN</country>
            </address>
          </addressbook>
        </applicant>
      </applicants>
      <inventors>
        <inventor sequence="1">
          <addressbook lang="eng">
            <name>Pratap, Ram</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="2">
          <addressbook lang="eng">
            <name>Gupta, Ram Chandra</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="3">
          <addressbook lang="eng">
            <name>Chander, Ramesh</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="4">
          <addressbook lang="eng">
            <name>Khanna, Ashok Kumar</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="5">
          <addressbook lang="eng">
            <name>Srivastava, Arvind Kumar</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="6">
          <addressbook lang="eng">
            <name>Raina, Deepak</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="7">
          <addressbook lang="eng">
            <name>Singh, Satyavan</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="8">
          <addressbook lang="eng">
            <name>Srivastava, Savita</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="9">
          <addressbook lang="eng">
            <name>Rastogl, Anil Kumar</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="10">
          <addressbook lang="eng">
            <name>Asthana, Omkar Prasad</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="11">
          <addressbook lang="eng">
            <name>Nityanand, Swarna</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="12">
          <addressbook lang="eng">
            <name>Anand, Nitya</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="13">
          <addressbook lang="eng">
            <name>Ghatak, Ashim</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="14">
          <addressbook lang="eng">
            <name>Kapoor, Narinder Kumar</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="15">
          <addressbook lang="eng">
            <name>Dev, Sukh</name>
            <address>
              <address-1>Central Drug Research Institute</address-1>
              <city>Lucknow 226 001 U.P.</city>
              <country>IN</country>
            </address>
          </addressbook>
        </inventor>
      </inventors>
      <agents>
        <agent sequence="1" rep-type="attorney">
          <addressbook lang="eng">
            <name>Florence, Julia Anne</name>
            <address>
              <address-1>Kilburn &amp; Strode, 20 Red Lion Street</address-1>
              <city>London WC1R 4PJ</city>
              <country>GB</country>
            </address>
          </addressbook>
        </agent>
      </agents>
    </parties>
    <designation-of-states date-changed="20081224">
      <designation-epc>
        <contracting-states>
          <country>DE</country>
          <country>FR</country>
          <country>GB</country>
          <country>IT</country>
        </contracting-states>
      </designation-epc>
    </designation-of-states>
    <patent-family date-changed="20151027">
      <main-family family-id="174320420">
        <family-member>
          <document-id>
            <country>EP</country>
            <doc-number>1020191</doc-number>
            <kind>A1</kind>
            <date>20000719</date>
          </document-id>
          <application-date>
            <date>19990331</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>DE</country>
            <doc-number>69940149</doc-number>
            <kind>D1</kind>
            <date>20090205</date>
          </document-id>
          <application-date>
            <date>19990331</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>EP</country>
            <doc-number>1020191</doc-number>
            <kind>B1</kind>
            <date>20081224</date>
          </document-id>
          <application-date>
            <date>19990331</date>
          </application-date>
        </family-member>
      </main-family>
      <complete-family family-id="174320419">
        <family-member>
          <document-id>
            <country>EP</country>
            <doc-number>1020191</doc-number>
            <kind>A1</kind>
            <date>20000719</date>
          </document-id>
          <application-date>
            <date>19990331</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>DE</country>
            <doc-number>69940149</doc-number>
            <kind>D1</kind>
            <date>20090205</date>
          </document-id>
          <application-date>
            <date>19990331</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>EP</country>
            <doc-number>1020191</doc-number>
            <kind>B1</kind>
            <date>20081224</date>
          </document-id>
          <application-date>
            <date>19990331</date>
          </application-date>
        </family-member>
      </complete-family>
    </patent-family>
  </bibliographic-data>
  <abstract id="abstr_eng" date-changed="20090520" lang="eng" format="equivalent" country="EP" doc-number="1020191" kind="A1">
    <p>The invention provides a method of using pregnadienones and pregnadienols represented by the structural formula (I) as shown herein below &lt;CHEM&gt; Wherein X=OH or O or combination thereof and positioning of olefinic bonds are at 4(5); 5(6); 6(17); 17(20) or various combinations and said compounds containing at least one olefinic bond in or on their D-ring for the treatment of hypolipidemic and hypoglycemic conditions in mammals, said method comprising administering an effective amount of the said compounds to the recipient mammals.</p>
  </abstract>
  <legal-data date-changed="20160511">
    <legal-event sequence="1">
      <publication-date>
        <date>20000719</date>
      </publication-date>
      <event-code-1>AK</event-code-1>
      <effect>+</effect>
      <legal-description>DESIGNATED CONTRACTING STATES:</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <corresponding-kind>A1</corresponding-kind>
      <legal-designated-states>
        <country>DE</country>
        <country>FR</country>
        <country>GB</country>
        <country>IT</country>
      </legal-designated-states>
    </legal-event>
    <legal-event sequence="2">
      <publication-date>
        <date>20000719</date>
      </publication-date>
      <event-code-1>AX</event-code-1>
      <effect>+</effect>
      <legal-description>REQUEST FOR EXTENSION OF THE EUROPEAN PATENT TO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <free-text-description>AL;LT;LV;MK;RO;SI</free-text-description>
    </legal-event>
    <legal-event sequence="3">
      <publication-date>
        <date>20010314</date>
      </publication-date>
      <event-code-1>17P</event-code-1>
      <effect>+</effect>
      <legal-description>REQUEST FOR EXAMINATION FILED</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <effective-date>
        <date>20010112</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="4">
      <publication-date>
        <date>20010328</date>
      </publication-date>
      <event-code-1>AKX</event-code-1>
      <effect>+</effect>
      <legal-description>PAYMENT OF DESIGNATION FEES</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <free-text-description>AT BE CH CY LI</free-text-description>
    </legal-event>
    <legal-event sequence="5">
      <publication-date>
        <date>20010530</date>
      </publication-date>
      <event-code-1>RBV</event-code-1>
      <effect>+</effect>
      <legal-description>DESIGNATED CONTRACTING STATES (CORRECTION):</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <legal-designated-states>
        <country>DE</country>
        <country>FR</country>
        <country>GB</country>
        <country>IT</country>
      </legal-designated-states>
    </legal-event>
    <legal-event sequence="6">
      <publication-date>
        <date>20011114</date>
      </publication-date>
      <event-code-1>17Q</event-code-1>
      <effect>+</effect>
      <legal-description>FIRST EXAMINATION REPORT</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <effective-date>
        <date>20010926</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="7">
      <publication-date>
        <date>20061115</date>
      </publication-date>
      <event-code-1>17Q</event-code-1>
      <effect>+</effect>
      <legal-description>FIRST EXAMINATION REPORT</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <effective-date>
        <date>20010926</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="8">
      <publication-date>
        <date>20080409</date>
      </publication-date>
      <event-code-1>RIC1</event-code-1>
      <legal-description>CLASSIFICATION (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <ipc>A61P   3/10        20060101ALI20080303BHEP</ipc>
    </legal-event>
    <legal-event sequence="9">
      <publication-date>
        <date>20080409</date>
      </publication-date>
      <event-code-1>RIC1</event-code-1>
      <legal-description>CLASSIFICATION (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <ipc>A61K  31/57        20060101AFI20080303BHEP</ipc>
    </legal-event>
    <legal-event sequence="10">
      <publication-date>
        <date>20080409</date>
      </publication-date>
      <event-code-1>RIC1</event-code-1>
      <legal-description>CLASSIFICATION (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <ipc>C07J   7/00        20060101ALI20080303BHEP</ipc>
    </legal-event>
    <legal-event sequence="11">
      <publication-date>
        <date>20080409</date>
      </publication-date>
      <event-code-1>RIC1</event-code-1>
      <legal-description>CLASSIFICATION (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <ipc>C07J  13/00        20060101ALI20080303BHEP</ipc>
    </legal-event>
    <legal-event sequence="12">
      <publication-date>
        <date>20080409</date>
      </publication-date>
      <event-code-1>RIC1</event-code-1>
      <legal-description>CLASSIFICATION (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <ipc>A61P   3/06        20060101ALI20080303BHEP</ipc>
    </legal-event>
    <legal-event sequence="13">
      <publication-date>
        <date>20080409</date>
      </publication-date>
      <event-code-1>RTI1</event-code-1>
      <legal-description>TITLE (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <free-text-description>MEDICAMENTS FOR HYPERLIPIDEMIC AND HYPERGLYCEMIC CONDITIONS</free-text-description>
    </legal-event>
    <legal-event sequence="14">
      <publication-date>
        <date>20081224</date>
      </publication-date>
      <event-code-1>AK</event-code-1>
      <effect>+</effect>
      <legal-description>DESIGNATED CONTRACTING STATES:</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <corresponding-kind>B1</corresponding-kind>
      <legal-designated-states>
        <country>DE</country>
        <country>FR</country>
        <country>GB</country>
        <country>IT</country>
      </legal-designated-states>
    </legal-event>
    <legal-event sequence="15">
      <publication-date>
        <date>20081224</date>
      </publication-date>
      <event-code-1>REG</event-code-1>
      <legal-description>REFERENCE TO A NATIONAL CODE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>GB</country>
      </designated-state-authority>
      <designated-state-event-code>FG4D</designated-state-event-code>
      <designated-state-description>EUROPEAN PATENT GRANTED</designated-state-description>
    </legal-event>
    <legal-event sequence="16">
      <publication-date>
        <date>20090205</date>
      </publication-date>
      <event-code-1>REF</event-code-1>
      <legal-description>CORRESPONDS TO:</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <corresponding-publication-number>69940149</corresponding-publication-number>
      <corresponding-authority>
        <country>DE</country>
      </corresponding-authority>
      <corresponding-publication-date>
        <date>20090205</date>
      </corresponding-publication-date>
      <corresponding-kind>P</corresponding-kind>
    </legal-event>
    <legal-event sequence="17">
      <publication-date>
        <date>20091202</date>
      </publication-date>
      <event-code-1>26N</event-code-1>
      <effect>+</effect>
      <legal-description>NO OPPOSITION FILED</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <effective-date>
        <date>20090925</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="18">
      <publication-date>
        <date>20120629</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>IT</country>
      </designated-state-authority>
      <payment-date>
        <date>20120321</date>
      </payment-date>
      <fee-payment-year>14</fee-payment-year>
    </legal-event>
    <legal-event sequence="19">
      <publication-date>
        <date>20120629</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>IT</country>
      </designated-state-authority>
      <payment-date>
        <date>20120321</date>
      </payment-date>
      <fee-payment-year>14</fee-payment-year>
    </legal-event>
    <legal-event sequence="20">
      <publication-date>
        <date>20120917</date>
      </publication-date>
      <event-code-1>REG</event-code-1>
      <legal-description>REFERENCE TO A NATIONAL CODE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>DE</country>
      </designated-state-authority>
      <designated-state-event-code>R082</designated-state-event-code>
      <designated-state-description>CHANGE OF REPRESENTATIVE</designated-state-description>
      <corresponding-publication-number>69940149</corresponding-publication-number>
      <corresponding-authority>
        <country>DE</country>
      </corresponding-authority>
      <representative-name>BOEHMERT &amp; BOEHMERT ANWALTSPARTNERSCHAFT MBB -, DE</representative-name>
    </legal-event>
    <legal-event sequence="21">
      <publication-date>
        <date>20120917</date>
      </publication-date>
      <event-code-1>REG</event-code-1>
      <legal-description>REFERENCE TO A NATIONAL CODE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>DE</country>
      </designated-state-authority>
      <designated-state-event-code>R082</designated-state-event-code>
      <designated-state-description>CHANGE OF REPRESENTATIVE</designated-state-description>
      <corresponding-publication-number>69940149</corresponding-publication-number>
      <corresponding-authority>
        <country>DE</country>
      </corresponding-authority>
      <representative-name>BOEHMERT &amp; BOEHMERT, DE</representative-name>
    </legal-event>
    <legal-event sequence="22">
      <publication-date>
        <date>20130430</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>FR</country>
      </designated-state-authority>
      <payment-date>
        <date>20130118</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="23">
      <publication-date>
        <date>20130430</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>FR</country>
      </designated-state-authority>
      <payment-date>
        <date>20130118</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="24">
      <publication-date>
        <date>20130731</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>GB</country>
      </designated-state-authority>
      <payment-date>
        <date>20130416</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="25">
      <publication-date>
        <date>20130731</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>DE</country>
      </designated-state-authority>
      <payment-date>
        <date>20130328</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="26">
      <publication-date>
        <date>20130731</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>GB</country>
      </designated-state-authority>
      <payment-date>
        <date>20130416</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="27">
      <publication-date>
        <date>20140430</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>DE</country>
      </designated-state-authority>
      <payment-date>
        <date>20140328</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="28">
      <publication-date>
        <date>20140430</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>DE</country>
      </designated-state-authority>
      <payment-date>
        <date>20140328</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="29">
      <publication-date>
        <date>20140530</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>FR</country>
      </designated-state-authority>
      <payment-date>
        <date>20140130</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="30">
      <publication-date>
        <date>20140530</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>IT</country>
      </designated-state-authority>
      <payment-date>
        <date>20140319</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="31">
      <publication-date>
        <date>20140530</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>IT</country>
      </designated-state-authority>
      <payment-date>
        <date>20140319</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="32">
      <publication-date>
        <date>20140530</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>FR</country>
      </designated-state-authority>
      <payment-date>
        <date>20140130</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="33">
      <publication-date>
        <date>20140630</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>GB</country>
      </designated-state-authority>
      <payment-date>
        <date>20140325</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="34">
      <publication-date>
        <date>20140630</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>GB</country>
      </designated-state-authority>
      <payment-date>
        <date>20140325</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="35">
      <publication-date>
        <date>20150430</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>IT</country>
      </designated-state-authority>
      <payment-date>
        <date>20150320</date>
      </payment-date>
      <fee-payment-year>17</fee-payment-year>
    </legal-event>
    <legal-event sequence="36">
      <publication-date>
        <date>20150430</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>IT</country>
      </designated-state-authority>
      <payment-date>
        <date>20150320</date>
      </payment-date>
      <fee-payment-year>17</fee-payment-year>
    </legal-event>
    <legal-event sequence="37">
      <publication-date>
        <date>20150529</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>FR</country>
      </designated-state-authority>
      <payment-date>
        <date>20150129</date>
      </payment-date>
      <fee-payment-year>17</fee-payment-year>
    </legal-event>
    <legal-event sequence="38">
      <publication-date>
        <date>20150529</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>FR</country>
      </designated-state-authority>
      <payment-date>
        <date>20150129</date>
      </payment-date>
      <fee-payment-year>17</fee-payment-year>
    </legal-event>
    <legal-event sequence="39">
      <publication-date>
        <date>20150529</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>GB</country>
      </designated-state-authority>
      <payment-date>
        <date>20150325</date>
      </payment-date>
      <fee-payment-year>17</fee-payment-year>
    </legal-event>
    <legal-event sequence="40">
      <publication-date>
        <date>20150731</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>DE</country>
      </designated-state-authority>
      <payment-date>
        <date>20150330</date>
      </payment-date>
      <fee-payment-year>17</fee-payment-year>
    </legal-event>
    <legal-event sequence="41">
      <publication-date>
        <date>20151229</date>
      </publication-date>
      <event-code-1>REG</event-code-1>
      <legal-description>REFERENCE TO A NATIONAL CODE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>FR</country>
      </designated-state-authority>
      <designated-state-event-code>PLFP</designated-state-event-code>
      <designated-state-description>FEE PAYMENT</designated-state-description>
      <fee-payment-year>18</fee-payment-year>
    </legal-event>
    <legal-event sequence="42">
      <publication-date>
        <date>20160229</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>FR</country>
      </designated-state-authority>
      <payment-date>
        <date>20151229</date>
      </payment-date>
      <fee-payment-year>18</fee-payment-year>
    </legal-event>
    <legal-event sequence="43">
      <publication-date>
        <date>20160429</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1020191A1</docdb-publication-number>
      <docdb-application-id>17400595</docdb-application-id>
      <designated-state-authority>
        <country>IT</country>
      </designated-state-authority>
      <payment-date>
        <date>20160304</date>
      </payment-date>
      <fee-payment-year>18</fee-payment-year>
    </legal-event>
  </legal-data>
  <description id="descr_eng" lang="eng" format="original" date-changed="20081224">
    <heading id="h-00001-en">
      <b>Field of the invention</b>
    </heading>
    <p id="p-00001-en" num="0001">This invention relates to the novel use of certain D-ring unsaturated pregnadienols/pregnadienones possessing both pronounced hypolipidemic and hypoglycemic activities and devoid of androgenic and progestational activities. More particularly this invention relates to the novel use of 3β-hydroxy-pregna-5, 16-dienone an important prototype of this class, represented by the formula (II) as shown in the accompanying drawings, for the treatment of diabetes and pronounced hypolipidemic and hypoglycemic activities</p>
    <heading id="h-00002-en">
      <b>Background</b>
    </heading>
    <p id="p-00002-en" num="0002">High plasma cholesterol and related lipids are known to be one of the factors that predispose an individual to atherosclerosis and thus to myocardial infraction. Diabetes mellitus, which eventually impairs the function of kidneys, eyes, nervous and vascular systems, is quite often associated with lipid disorders. Both hyperlipidemia and diabetes mellitus require long term management and pose problems in choice of pharmacotherapeutic interventions when these conditions manifest together. Though a number of drugs are known separately to treat these conditions, there are a number of side effects associated with them which limit their long term use.</p>
    <p id="p-00003-en" num="0003">The most important hypolipidemic drugs available today belong to the statin and fibrate classes [<nplcit id="ncit-00001" npl-type="s"><text>McCarthy, P.A., Med. Res. Rev., 13, 139-59 (1993</text></nplcit>)] whereas hypoglycemic drugs fall into the category of sulphonylureas, biguanidines and amidines [<nplcit id="ncit-00002" npl-type="b"><text>Wolff, M.E. (Ed), Burger's Medicinal Chemistry Part II, 1045 (1981), John Wiley &amp; Sons, New York</text></nplcit>]. However, these therapeutic agents are not free of side effects-statins (HMG-CoA reductase inhibitors) the most widely used drugs today which hitherto were thought to be very safe drugs, have exhibited side effects following long term therapy [<nplcit id="ncit-00003" npl-type="s"><text>Carrier, M. et al.; Ann. Thorac. Surg., 57, 353-6 (1994</text></nplcit>)]. The adverse effects which have become the source of concern, are increases in hepatic transaminases and myopathies [Witztum, J.L., In <nplcit id="ncit-00004" npl-type="b"><text>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics, eds. Hardman, J. et al., 9th edition, McGraw Hill, New York pp. 875-98</text></nplcit>, <nplcit id="ncit-00005" npl-type="s"><text>Fukami, M. et al; Res. Exp. Med., 193, 263-73 (1993</text></nplcit>); <nplcit id="ncit-00006" npl-type="s"><text>Appelkvist, E..; et al.; Clin. Invest., 71 (suppl 8), 597-102 (1993</text></nplcit>), <nplcit id="ncit-00007" npl-type="s"><text>Wills, R.A. et al.; Proc. Natl. Acad. Sci. (US), 87, 8928-30 (1990</text></nplcit>)] and carcinogenesis specially breast cancer in subjects undergoing treatment with pravastatin [<nplcit id="ncit-00008" npl-type="s"><text>Braunwald, E.; Scrip, 2117, 33 (1996</text></nplcit>)); <nplcit id="ncit-00009" npl-type="s"><text>Ciaravino, V. et al.; Mutat. Res.; 353, 95-107 (1995</text></nplcit>)]. The incidence of myopathy associated with rhabdomyolysis and renal failure is increased subsequent to such treatment [<nplcit id="ncit-00010" npl-type="s"><text>East, C. et al.; N. Engl. J. Med., 318, 47-48 (1998</text></nplcit>); <nplcit id="ncit-00011" npl-type="s"><text>Pierce L.R. et al.; J. Am.Med. Assoc., 265, 71-75 (1990</text></nplcit>)]. Also, these HMG-CoA inhibitors block mevalonate production which occurs at an early stage in cholesterol synthetic pathway. Mevalonate is a common precursor for all isoprenoids such as ubiquinones (Co-enzyme Q-10), the dolichols, isopentenyl t-RNA etc. Therefore, long term blockade of mevalonate synthesis leads to Q-10 deficiency. Serum Co-enzyme Q-10 is important for cardiac function {<nplcit id="ncit-00012" npl-type="s"><text>Laaksonen, R. et al., Eur. J. Clin. Pharmacol. 46,313-7 (1994</text></nplcit>); <nplcit id="ncit-00013" npl-type="s"><text>Bargossi, A.M. et al; Int.J. Clin. Lab. Res., 24, 171-6 (1994</text></nplcit>)]. The commonest side-effects of fibrates and particularly clofibrate therapy are gastrointestinal upsets including nausea, vomiting, diarrhoea, dyspepsia, flatulence and abdominal discomfort [<nplcit id="ncit-00014" npl-type="s"><text>Oliver M. F. et al.; Br. Heart J., 40, 1069-1118 (1978</text></nplcit>)]. Elevated creatine phosphokinase concentration during clofibrate therapy may be associated with a syndrome of muscle pain and weakness. Large-scale long-term studies have demonstrated an increased incidence of cholecystitis, gallstones and sometimes pancreatitis in patients receiving clofibrate and some studies have indicated cardiovascular disorders [<nplcit id="ncit-00015" npl-type="s"><text>The coronary Drug Project Research Group; N. Engl. J. Med., 296, 1185-90 (1977</text></nplcit>)]. The unexpected finding of an increased mortality rate in patients taking clofibrate in the WHO study produced serious concern over the long-term safely of clofibrate and ultimately led to its withdrawal in many countries [<nplcit id="ncit-00016" npl-type="s"><text>Oliver, M. F. et al ; Lancet, ii, 600-604 (1984</text></nplcit>)].</p>
    <p id="p-00004-en" num="0004">The adverse effects of biguanidine antidiabetic agents include gastro-intestinal disturbances like diarrhoea and lactic acidosis [<nplcit id="ncit-00017" npl-type="s"><text>Paterson, K. R. et al.; Adverse Drug React Acute Poisoning Rev., 3, 173-82 (1984</text></nplcit>)]. With sulphonylureas the commonly associated adverse effects are hypoglycemia, gastrointestinal disturbances, hypersensitivity and vascular complications [<nplcit id="ncit-00018" npl-type="s"><text>Paice, BJ. et al., Adverse Drug React. Acute Poisoning, 4, 23-26 (1985</text></nplcit>)]. As diabetes and hyperlipidemia are quite commonly manifesting together, it would be of great clinical benefit if the same compound could have both these activities together because the available drugs are not free of toxic effects and neither data regarding toxic manifestations are available when drugs for two clinical conditions are mixed together.</p>
    <p id="p-00005-en" num="0005">Two approaches currently being pursued in search of drugs with hypolipidemic and hypoglycemic activities together. The first approach emerged during detailed study of antihypertensive action of adrenergic receptor modulators. The study revealed that α<sub>1</sub>-adrenergie blockers (particularly Doxazosin and Prazosin) [<nplcit id="ncit-00019" npl-type="s"><text>Lithell, H.O. ; J. Hypertens,15 (Suppl 1), S 39-42 (1997</text></nplcit>); <nplcit id="ncit-00020" npl-type="s"><text>Poliare,T. et al.; Diabetologia, 31, 415-420 (1988</text></nplcit>); <nplcit id="ncit-00021" npl-type="s"><text>Anderson, P.E. et al.; Am. J. Hypertens, 9, 323-333 (1996</text></nplcit>)] and β<sub>3</sub>-adrenergie agonist (BTA-243, BRL-37344, CGP 12177, CL 316243 [<nplcit id="ncit-00022" npl-type="s"><text>Arch, J. R. S. et al.; Med. Res. Rev., 13, 663-729 (1993</text></nplcit>); <nplcit id="ncit-00023" npl-type="s"><text>Largis, E. E. ct al;. Drug Dev. Res.. 32, 69-76 (1994</text></nplcit>)] also affect plasma lipoprotein metabolism and increase insulin sensitivity. As a result such antihypertensive drugs exhibit lipid lowering and hypoglycemic actions together, α<sub>1</sub>-adrenergie receptor blockers, however have the inherent limitations of causing orthostatic hypotension and syncope [<nplcit id="ncit-00024" npl-type="s"><text>Matyus, P.; Med. Res. Rev., 17(6), 523-35 (1997</text></nplcit>)]. The essential requirement of β<sub>3</sub>-agonist for antiobesity and antidiabetic actions is the need for high selectivity for β<sub>3</sub>-adrenoceptor. Any substantial β<sub>1</sub>- or β<sub>2-</sub> agonism would likely cause increased heart rate and muscle tremor respectively which are unacceptable in a drug which could be administered on long term basis [<nplcit id="ncit-00025" npl-type="s"><text>Connacher, A . A. et al.; Brit. Med. J., 296, 1217-20 (1988</text></nplcit>); <nplcit id="ncit-00026" npl-type="s"><text>Mitchell, T. H. et al; Int. J. Obesity., 13(6), 757-66 (1989</text></nplcit>)]. The second line of approach for dual activity came into light during the study of anti-oxidant property of drugs. There have been many reports describing relationships between peroxidation and diseases such as diabetes mellitus, atherosclerosis and myocardial ischemia in terms of radical oxidation. Troglitazone, an antioxidant drug has been developed as an oral hypoglycemic agent which enhances the action of insulin in peripheral tissues and liver besides its hypolipidemic effects. However, troglitazone is also not free of major side effect causing liver damage. The drug, troglitazone, has been implicated in 35 cases of liver disease leading to one transplant and one death (<nplcit id="ncit-00027" npl-type="s"><text>Warner-Lambert; Chem. &amp; Ind., No.22. 897 (1997</text></nplcit>)]. Thus to the best of out knowledge no class of compound is yet available which has both effects together as the main action and have fair safety margin.</p>
    <p id="p-00006-en" num="0006">We, in early eighties started our work for search of such compounds which have effect on endogenous transportation of lipids and glucose rather than interfering with exogenous transportation. Our research was mainly based on secondary metabolic actions of progesterone.</p>
    <p id="p-00007-en" num="0007">Progesterone, apart from its classical hormonal action on the reproductive system, is known to modulate lipid, carbohydrate, insulin and protein metabolism. The rise in the level of progesterone in the first trimester of pregnancy causes hyperphagia, pancreatic islet hypertrophy, hyperinsulinemia and body fat and glycogen deposition, when the metabolic demands of the fetus are very low. However, in the latter half of pregnancy, although the progesterone levels are still high, the carbohydrate, lipid and protein reservoirs shift into circulation to meet the needs of the growing fetus. [<nplcit id="ncit-00028" npl-type="s"><text>Kalkhoff, R.K.; Am. J. Obstet. Gynecol., 142, 735-38 (1982</text></nplcit>)].</p>
    <p id="p-00008-en" num="0008">Progesterone thus, having actions both on the reproductive and the metabolic systems, seemed to offer the possibility of dissociating these two biological activities by structural modifications. The experience of the development of second generation progestins supported this contention. The first generation progestins such as levonorgestrel exhibited undesirable pharmacologic effects like alteration in carbohydrate and lipoprotein metabolism, weight gain and hypertension, which was shown to be related to their intrinsic androgenic/anabotic activity and ability to bind with androgen receptors. The androgenic affinity has been attributed to C-17 hydroxy functionality which makes these molecules resemble androgens. In recently discovered second generation progestins such as gestodene and 3-keto-desogestrel, an additional olefinic bond either in C- or D- ring brought a dramatic decrease in their affinity to androgen receptors (Table 1). As a result these compounds have a very high order of progestational effect with practically no androgenic activity and did not cause hyperlipidemia [ <nplcit id="ncit-00029" npl-type="s"><text>London, R.S.; Obstetrical &amp; Gynocological Survey, 47, 777-81 (1992</text></nplcit>)]. <tables id="tables-00001-en" num="0001"><table frame="all"><title>Table 1. Relative Binding Affinity of Contraceptive Progestins for Progesterone and Androgen receptors</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="41mm" /><colspec colnum="2" colname="col2" colwidth="42mm" /><colspec colnum="3" colname="col3" colwidth="41mm" /><colspec colnum="4" colname="col4" colwidth="43mm" /><thead><row><entry valign="top" /><entry align="center" valign="top"><b>Progestin Receptor Binding Affinity</b></entry><entry align="center" valign="top"><b>Androgen Receptor Binding Affinity</b></entry><entry align="center" valign="top"><b>Selectivity Index* (A/P ratio)</b></entry></row></thead><tbody><row><entry>Progesterone</entry><entry align="center">1.00</entry><entry align="char" char=".">0.005</entry><entry align="center">93</entry></row><row><entry>Levonorgestrel</entry><entry align="center">5.41</entry><entry align="char" char=".">0.220</entry><entry align="center">11</entry></row><row><entry>3-Keto-desogestrel</entry><entry align="center">8.6</entry><entry align="char" char=".">0.120</entry><entry align="center">33</entry></row><row><entry>Gestodene</entry><entry align="center">9.21</entry><entry align="char" char=".">0.154</entry><entry align="center">28</entry></row></tbody></tgroup><tgroup cols="4" rowsep="0"><colspec colnum="1" colname="col1" colwidth="41mm" /><colspec colnum="2" colname="col2" colwidth="42mm" /><colspec colnum="3" colname="col3" colwidth="41mm" /><colspec colnum="4" colname="col4" colwidth="43mm" /><tbody><row><entry namest="col1" nameend="col4" align="justify">* The higher the selectivity index, the greater the separation between the dose needed to achieve the desired progestational effect and the dose associated with the undesired androgenic effect [<nplcit id="ncit-00030" npl-type="s"><text>Collins. D.C., Am. J. Obstet. Gynecol 170, 1508-13 (1994</text></nplcit>)].</entry></row></tbody></tgroup></table></tables></p>
    <heading id="h-00003-en">
      <b>Objects of the invention</b>
    </heading>
    <p id="p-00009-en" num="0009">It is an object of the invention to explore the possibility of designing pregnadienones which while preserving the ability to modulate lipid and carbohydrate metabolism would not have any progestational effect. It would be pertinent to point out that earlier, the applicants had isolated a D-ring modified pregnenolone, named Gugulsterone represented by formula (9) as shown in Table 2, from guggul resin obtained from <i>Commiphora mukul,</i> which had potent hypolipidemic effect without any progestational effect [<nplcit id="ncit-00031" npl-type="s"><text>Arya, V.P.; Drugs Fut. 13, 618 (1998</text></nplcit>)].</p>
    <p id="p-00010-en" num="0010">It is another object of the invention to explore the possibility of dissociating the hypolipidemic and insulin sensitizing activities of progesterone from its hormonal actions. Accordingly, the applicants focussed their attention to prepare and investigate analogues/prototypes with additional substituents in ring-D of pregnadienones.</p>
    <heading id="h-00004-en">
      <b>Brief description of the accompanying drawings</b>
    </heading>
    <p id="p-00011-en" num="0011">
      <ul id="ul-00001-en" list-style="none">
        <li>Figure 1 (I) represents the structural formula of compounds belonging to the class of pregnadienones and pregnadienols in general</li>
        <li>Figure 1 (II) represents the structural formula of 3β-hydroxypregna-5, 16-dien-20-one</li>
        <li>Figure 2 represents the structural formulae of hormones.</li>
      </ul>
    </p>
    <heading id="h-00005-en">
      <b>Summary of the invention</b>
    </heading>
    <p id="p-00012-en" num="0012">In accordance with the above objectives, the applicant's present invention relates to the use of D-ring unsaturated pregnadienones selected from the group consisting of 3β-hydroxypregna-5,16-dien-20-one 4,16-dienpregna-3,20-dione, 3β-hydroxypregna-5-en-20-one, 5,16-dien-pregnane-3,20-diol and 5,17(20)-dienpregna-3,16-diol which causes significant fall of serum cholesterol, triglycerides, LDL-cholesterol and glucose with mild increase in HDL-cholesterol. The compounds possess fair safety margin having antioxidant and cardio protection activities.</p>
    <p id="p-00013-en" num="0013">The invention also provides a compound for use in the treatment of hyperlipidemic and hyperglycemic conditions.</p>
    <heading id="h-00006-en">
      <b>Detailed description of the invention</b>
    </heading>
    <p id="p-00014-en" num="0014">The present invention concerns methods for lowering serum cholesterol, triglycerides and glucose levels in subjects with obesity and diabetic conditions or prophylactically holding in check the symptoms of such a disease state.</p>
    <p id="p-00015-en" num="0015">In particular, the applicants, during their study, have observed that the pregnadienone, 3β-hydroxypregna-5, 16-dien-20-one represented by the structural formula (II) shown hereinbelow and in the accompanying drawings is useful for the treatment of hyperlipidemic and hyperglycemic conditions. <chemistry id="chem-00001-en" num="0001"><img id="img-00001-en" wi="53" he="42" img-content="chem" file="imgb0001.tif" img-format="tif" /></chemistry></p>
    <p id="p-00016-en" num="0016">Accordingly, the invention provides the use of a compound selected from the group consisting of 3β-hydroxypregna-5,16-dien-20-one, 4,16-dienpregna-3, 20-dione, 3β-hydroxypregna-5-en-20-one, 5,16-dien-pregnane-3, 20-diol and 5,17(20)-dienpregna-3,16-diol in the manufacture of a medicament for the treatment or prophylaxis of a hyperlipidemic and/or hyperglycemic condition.</p>
    <p id="p-00017-en" num="0017">In another embodiment, the invention provides the use of a compound selected from the group consisting of 3β-hydroxypregna-5,16-dien-20-one, 4,16-dienpregna-3, 20-dione, 3β-hydroxypregna-5-en-20-one, 5,16-dien-pregnane-3, 20-diol and 5,17(20)-dienpregna-3,16-diol in the manufacture of a medicament for the treatment or prophylaxes of a diabetic condition.</p>
    <p id="p-00018-en" num="0018">In another embodiment, the invention provides the use of a compound listed above in the manufacture of a medicament for lowering serum cholesterol , triglyceride and/or glucose levels in a subject with obesity or a diabetic condition.</p>
    <p id="p-00019-en" num="0019">In another embodiment, the medicament is in the form of a tablet, capsule or injectible.</p>
    <p id="p-00020-en" num="0020">In another embodiment, the compounds of the formula (I) are characterised as a pregnadienone or pregnadienol.</p>
    <p id="p-00021-en" num="0021">In yet another embodiment, the most preferred compound belonging to the family of pregnadienones and pregnadienols represented by formula (I) is 3β-hydroxy-pregna-5,16-dien-20-one, which is represented by the structural formula (II) as shown above.</p>
    <p id="p-00022-en" num="0022">In a further embodiment, the invention provides the compounds listed above optionally administered as an admixture with one or more other therapeutic agents selected from anti-platelet aggregation, anti artherosclerotic, hypolipoproteinic and antidiabetic drugs.</p>
    <p id="p-00023-en" num="0023">In a final embodiment, the invention provides a compound listed above for use in the treatment of a hyperlipidemic and/or hyperglycemic condition.</p>
    <heading id="h-00007-en">
      <b>Methods of synthesis/production</b>
    </heading>
    <p id="p-00024-en" num="0024">The methods of synthesis are essentially known in the literature. 3β-hydroxy-pregna-5,16-dien-20-one can be obtained from diosgenin by chemical degradation [<nplcit id="ncit-00032" npl-type="s"><text>G. Rosenleranz "History of Steroids", Steroids, 57, 409 (1992</text></nplcit>)]. Although, it was later isolated from Vertrum Grandiflorum [<nplcit id="ncit-00033" npl-type="s"><text>Kanko, K et al; Phytochemistry, 12 1509 (1973</text></nplcit>)] but yield is too low to be of any practical value. Oppenauer oxidation of 2 with aluminium-<i>iso</i>proxide and cyclohexanone in toluene produces 4,16-dienpregna-3,20-dione [16-dehydroprogesterone, (3)]. The C-16 (17) olefinic bond in 1 is selectively reduced with Pd-C in diethylether at very low hydrogen gas pressure. The resultant product 4 on basic hydrolysis furnishes 5. The procedure of <nplcit id="ncit-00034" npl-type="s"><text>Benn and Dodson [J. Org. Chem. 29, 1142 (1964</text></nplcit>)] was followed for the preparation of Gugulsterone (9). The reduction of 16-DPA (1) with lithium aluminium hydride produces diol <b>6</b> which after Sigmatropic rearrangement in presence of p-toluenesulphonic acid, acetic acid and acetic anhydride produces the diacetate 7. Basic hydrolysis of the diacetate 7 followed by Oppenauer oxidation furnishes an 80 : 20 mixture of E&amp;Z- Gugulsterone (9).</p>
    <heading id="h-00008-en">
      <b>5. BIOLOGICAL ACTIVITY</b>
    </heading>
    <heading id="h-00009-en">
      <b>5.1 Hypolipidemic Activity</b>
    </heading>
    <p id="p-00025-en" num="0025">The primary hypolipidemic effect of these compounds were established in triton induced hyperlipidemia in Charles Foster rats. The compounds which exhibited significant lipid lowering effect in this model were then evaluated for their hypolipidemic effect in normal, and diet induced hyperlipidemic rats, rabbits and rhesus monkeys.</p>
    <heading id="h-00010-en">
      <b>5.1.1. Hypolipidemic Activity In Triton Treated Rats</b>
    </heading>
    <p id="p-00026-en" num="0026">The cholesterol lowering effect of some representative compounds of pregrenadienols and pregrenadienones as compared to clofibrate and gugulsterone in triton treated Charles Foster rats is described in Table-2 <tables id="tables-00002-en" num="0002"><table frame="all"><title><b>Table-2 : Cholesterol lowering effect of pregnane compounds as compared to Clofibrate in Triton treated rats</b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="28mm" /><colspec colnum="2" colname="col2" colwidth="32mm" /><colspec colnum="3" colname="col3" colwidth="46mm" /><colspec colnum="4" colname="col4" colwidth="30mm" /><colspec colnum="5" colname="col5" colwidth="32mm" /><thead><row><entry align="center" valign="middle"><b>Compd. No.</b></entry><entry align="center" valign="middle"><b>Compound</b></entry><entry align="center" valign="middle"><b>Structure</b></entry><entry align="center" valign="middle"><b>Dose (i.p.) mg/kg</b></entry><entry align="center" valign="middle"><b>% Change S. Chol.</b></entry></row></thead><tbody><row><entry align="center">Reference 1</entry><entry>3β-Acetoxypregna-5.16-dien-20-one (16-DPA)</entry><entry align="center"><chemistry id="chem-00002-en" num="0002"><img id="img-00002-en" wi="38" he="22" img-content="chem" file="imgb0002.tif" img-format="tif" /></chemistry></entry><entry align="center" valign="middle">50</entry><entry align="center" valign="middle">-43</entry></row><row><entry align="center">2</entry><entry>3β-Hydroxypregna-5,16-dien-20-one</entry><entry align="center"><chemistry id="chem-00003-en" num="0003"><img id="img-00003-en" wi="38" he="24" img-content="chem" file="imgb0003.tif" img-format="tif" /></chemistry></entry><entry align="center" valign="middle">50</entry><entry align="center" valign="middle">-46</entry></row><row><entry align="center">3</entry><entry>4.16-Dinpregna-3,20-dione</entry><entry align="center"><chemistry id="chem-00004-en" num="0004"><img id="img-00004-en" wi="39" he="25" img-content="chem" file="imgb0004.tif" img-format="tif" /></chemistry></entry><entry align="center" valign="middle">50</entry><entry align="center" valign="middle">-13</entry></row><row><entry align="center">Reference 4</entry><entry>3β-Acetoxypregna-5-en-20-one</entry><entry align="center"><chemistry id="chem-00005-en" num="0005"><img id="img-00005-en" wi="39" he="23" img-content="chem" file="imgb0005.tif" img-format="tif" /></chemistry></entry><entry align="center" valign="middle">100</entry><entry align="center" valign="middle">-12</entry></row><row><entry align="center">5</entry><entry>3β-Hydroxypregna-5-en-20-one</entry><entry align="center"><chemistry id="chem-00006-en" num="0006"><img id="img-00006-en" wi="38" he="23" img-content="chem" file="imgb0006.tif" img-format="tif" /></chemistry></entry><entry align="center" valign="middle">100</entry><entry align="center" valign="middle">-09</entry></row><row><entry align="center">6</entry><entry>5,16-Dien-pregnane-3,20-diol</entry><entry align="center"><chemistry id="chem-00007-en" num="0007"><img id="img-00007-en" wi="39" he="30" img-content="chem" file="imgb0007.tif" img-format="tif" /></chemistry></entry><entry align="center" valign="middle">50</entry><entry align="center" valign="middle">-10</entry></row><row><entry align="center">Reference 7</entry><entry>5,17(20)-Dienpregna-3,16-diol-diacetate</entry><entry align="center"><chemistry id="chem-00008-en" num="0008"><img id="img-00008-en" wi="40" he="26" img-content="chem" file="imgb0008.tif" img-format="tif" /></chemistry></entry><entry align="center" valign="middle">50</entry><entry align="center" valign="middle">-33</entry></row><row><entry align="center">8</entry><entry>5,17(20)-Dienpregna-3,16-diol</entry><entry align="center"><chemistry id="chem-00009-en" num="0009"><img id="img-00009-en" wi="42" he="27" img-content="chem" file="imgb0009.tif" img-format="tif" /></chemistry></entry><entry align="center" valign="middle">50</entry><entry align="center" valign="middle">-31</entry></row><row><entry align="center">9</entry><entry align="center">Gugulsterone</entry><entry align="center"><chemistry id="chem-00010-en" num="0010"><img id="img-00010-en" wi="38" he="22" img-content="chem" file="imgb0010.tif" img-format="tif" /></chemistry></entry><entry align="center" valign="middle">50</entry><entry align="center" valign="middle">-44</entry></row><row><entry align="center">10</entry><entry align="center">Clofibrate</entry><entry align="center" /><entry align="center" valign="middle">200</entry><entry align="center" valign="middle">-15</entry></row></tbody></tgroup></table></tables></p>
    <p id="p-00027-en" num="0027">The results showed that of the compounds tested, the highest effect was exhibited by 16-DPA (1) and its 3-des-acetyl analog <b>2</b> comparable to gugulsterone (9), and that the removal of double bond in ring D of 1 or <b>2</b> almost abolished the effect.</p>
    <heading id="h-00011-en">
      <b>5.1.2 Hypolipidemic Activity of 3β-Hydroxypregna-5,16-dien-20-one (2) in Normal Rats</b>
    </heading>
    <p id="p-00028-en" num="0028">In normal rats, 3β-hydroxypregna-5,16-dien-20-one (2), at 50 mg/kg produced a significant lowering of serum cholesterol and triglycerides as describe in Table-3 below. The animals did not develop any tolerance to the compound even after administering for 30 days. <tables id="tables-00003-en" num="0003"><table frame="all"><title><b>Table 3. Hypolipidemic activity of 3β-Hydroxypregna-5,16-dien-20-one (2) in normal rats</b></title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="35mm" /><colspec colnum="2" colname="col2" colwidth="22mm" /><colspec colnum="3" colname="col3" colwidth="22mm" /><colspec colnum="4" colname="col4" colwidth="17mm" /><colspec colnum="5" colname="col5" colwidth="35mm" /><colspec colnum="6" colname="col6" colwidth="37mm" /><thead><row rowsep="0"><entry morerows="1" rowsep="1" valign="middle"><b>Treatment</b></entry><entry namest="col2" nameend="col3" align="center" valign="middle"><b>Serum Cholesterol (mg%)</b></entry><entry morerows="1" rowsep="1" align="center" valign="middle"><b>%Fall</b></entry><entry morerows="1" rowsep="1" align="center" valign="middle"><b>Serum Triglycrides (mg%) 30 Days</b></entry><entry morerows="1" rowsep="1" align="center" valign="middle"><b>% Fall compared to control</b></entry></row><row><entry align="center" valign="middle"><b>0 Days</b></entry><entry align="center" valign="middle"><b>30 Days</b></entry></row></thead><tbody><row><entry valign="middle">2 (50 mg/kg) (8)</entry><entry align="center" valign="middle">71.5±1.8</entry><entry align="center" valign="middle">43.2±2.9</entry><entry align="center" valign="middle">40</entry><entry align="center" valign="middle">42.0±2.8</entry><entry align="center" valign="middle">35</entry></row><row><entry valign="middle">Clofibrate (50 mg/kg.) (6)</entry><entry align="center" valign="middle">82.3±3.3</entry><entry align="center" valign="middle">53.2±2.0</entry><entry align="center" valign="middle">36</entry><entry align="center" valign="middle">47.3±3.2</entry><entry align="center" valign="middle">28</entry></row><row><entry valign="middle">Normal saline (control) (6)</entry><entry align="center" valign="middle">83.3±3.</entry><entry align="center" valign="middle">80.1±1.4</entry><entry align="center" valign="middle">-</entry><entry align="center" valign="middle">65.2±2.9</entry><entry align="center" valign="middle" /></row></tbody></tgroup><tgroup cols="6" rowsep="0"><colspec colnum="1" colname="col1" colwidth="35mm" /><colspec colnum="2" colname="col2" colwidth="22mm" /><colspec colnum="3" colname="col3" colwidth="22mm" /><colspec colnum="4" colname="col4" colwidth="17mm" /><colspec colnum="5" colname="col5" colwidth="35mm" /><colspec colnum="6" colname="col6" colwidth="37mm" /><tbody><row><entry namest="col1" nameend="col6" align="justify"><i>Mean values</i> ± <i>SD. Figure in parenthesis represent number of animals.</i></entry></row></tbody></tgroup></table></tables></p>
    <heading id="h-00012-en">
      <b>5.1.3 Hypolipidemic Activity in Diet Induced Hyperlipidemic Rats</b>
    </heading>
    <p id="p-00029-en" num="0029">Twenty three normal male rats average weight 110-120 g were taken for study and were divided into four groups. Group I: animals recived special diet and 3β-hydroxypregna-5, 16-dien-20-one (2) 50 mg/kg p.o. in 1% gum acacia Group II: animals received 3β-hydroxpregna-5. 16-dien-20-one (2). 100 mg/kg p.o. in 1% gum acacia and special diet. Group III animals received special fat diet and 1% gum acacia and served as control. Group IV: animals were fed with stock diet and served as normal control. All animals were sacrificed at the end of 36 days. Blood was drawn from the tail at 10 days and from the aorta at the time of sacrifice for estimation of serum cholesterol, triglycerides and HDL-cholesterol. LDL-cholesterol was calculated as described.<br /> [<nplcit id="ncit-00035" npl-type="b"><text>Roschlau.P. In: Methods of Enzymatic Analysis 4th ed., H.U. Bergmeyer. Ed (Academic Press. New York ) 1975 p 1890</text></nplcit>; <nplcit id="ncit-00036" npl-type="b"><text>Wahlefield, W.A. In: Methods of Enzymatic Analysis, 4th ed.: I I.U. Bergmeyer, Ed.(Academic Press, New York) 1974 p 1831</text></nplcit>.]</p>
    <heading id="h-00013-en">
      <b>Results</b>
    </heading>
    <p id="p-00030-en" num="0030">Animals treated with 3β-hydroxypregna-5, 16-dien-20-one (2), at 50 and 100 mg/kg showed a significant lowering in serum cholesterol by 31 and 59%, triglycerides by 55 and 62%. LDL-cholesterol by 27 and 74% respectively (Table - 4 &amp; 5). <tables id="tables-00004-en" num="0004"><table frame="all"><title><b>Table-4. Effect of 3β-Hydroxypregna-5,16-dien-20-one (2) on serum cholesterol and triglycerides in hyperlipidemic rats</b></title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="28mm" /><colspec colnum="2" colname="col2" colwidth="28mm" /><colspec colnum="3" colname="col3" colwidth="28mm" /><colspec colnum="4" colname="col4" colwidth="28mm" /><colspec colnum="5" colname="col5" colwidth="28mm" /><colspec colnum="6" colname="col6" colwidth="29mm" /><thead><row><entry morerows="1" align="center" valign="middle"><b>Treatment</b></entry><entry namest="col2" nameend="col4" align="center" valign="middle"><b>Serum Cholesterol (mg%) Days</b></entry><entry namest="col5" nameend="col6" align="center" valign="middle"><b>Serum Triglycerides (mg%)</b></entry></row><row><entry align="center" valign="middle"><b>0</b></entry><entry align="center" valign="middle"><b>10</b></entry><entry align="center" valign="middle"><b>36</b></entry><entry align="center" valign="middle"><b>0</b></entry><entry align="center" valign="middle"><b>36</b></entry></row></thead><tbody><row><entry align="center" valign="middle">I 2(50mg/kg)+HFD</entry><entry align="center" valign="middle">69.1±9.9 (7)</entry><entry align="center" valign="middle">212.4±23.8 (7)</entry><entry align="center" valign="middle">165±26.7 (7)</entry><entry align="center" valign="middle">48.8±7.0 (6)</entry><entry align="center" valign="middle">61.5±10.5 (6)</entry></row><row><entry align="center" valign="middle">%Decrease (Compound to group III)</entry><entry align="center" valign="middle" /><entry align="center" valign="middle"><b>16</b></entry><entry align="center" valign="middle"><b>31</b></entry><entry align="center" valign="middle" /><entry align="center" valign="middle"><b>55</b></entry></row><row><entry align="center" valign="middle">II 2(100mg/kg)+HFD</entry><entry align="center" valign="middle">60.8±10.3 (6)</entry><entry align="center" valign="middle">145.5±10.6 (6)</entry><entry align="center" valign="middle">106.4±4.6 (5)</entry><entry align="center" valign="middle">50±7.1 (5)</entry><entry align="center" valign="middle">53.0±7.5 (5)</entry></row><row><entry align="center" valign="middle">%Decrease (Compound to group III)</entry><entry align="center" valign="middle" /><entry align="center" valign="middle"><b>48</b></entry><entry align="center" valign="middle"><b>59</b></entry><entry align="center" valign="middle" /><entry align="center" valign="middle"><b>62</b></entry></row><row><entry align="center" valign="middle">III HFD</entry><entry align="center" valign="middle">73.2±5.8 (5)</entry><entry align="center" valign="middle">325±29.8 (5)</entry><entry align="center" valign="middle">293.2±16.6 (5)</entry><entry align="center" valign="middle">48.75±5.1 (4)</entry><entry align="center" valign="middle">137.5±8.5 (4)</entry></row><row><entry align="center" valign="middle">IV Normal Diet</entry><entry align="center" valign="middle" /><entry align="center" valign="middle">72±7.1 (5)</entry><entry align="center" valign="middle" /><entry align="center" valign="middle" /><entry align="center" valign="middle">48.2±4.3 (5)</entry></row></tbody></tgroup><tgroup cols="6" rowsep="0"><colspec colnum="1" colname="col1" colwidth="28mm" /><colspec colnum="2" colname="col2" colwidth="28mm" /><colspec colnum="3" colname="col3" colwidth="28mm" /><colspec colnum="4" colname="col4" colwidth="28mm" /><colspec colnum="5" colname="col5" colwidth="28mm" /><colspec colnum="6" colname="col6" colwidth="29mm" /><tbody><row><entry namest="col1" nameend="col6" align="justify"><i>HFD</i>= <i>High fat diet, Values are Mean</i> ± <i>SD. Figures in parenthesis are number of animals</i></entry></row></tbody></tgroup></table></tables><tables id="tables-00005-en" num="0005"><table frame="all"><title><b>Table-5</b>. Effect of 3β-Hydroxypregna-5,16-dien-20-one (2) on HDL and LDL-cholesterol in hyperlipidemic rats</title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="36mm" /><colspec colnum="2" colname="col2" colwidth="30mm" /><colspec colnum="3" colname="col3" colwidth="30mm" /><colspec colnum="4" colname="col4" colwidth="30mm" /><colspec colnum="5" colname="col5" colwidth="34mm" /><thead><row><entry morerows="1" align="center" valign="middle"><b>Treatment</b></entry><entry namest="col2" nameend="col3" align="center" valign="middle"><b>HDL-Cholesterol (mg%)</b></entry><entry namest="col4" nameend="col5" align="center" valign="middle"><b>LDL-Cholesterol (mg%)</b></entry></row><row><entry align="center" valign="middle"><b>Day 0</b></entry><entry align="center" valign="middle"><b>Day 36</b></entry><entry align="center" valign="middle"><b>Day 0</b></entry><entry align="center" valign="middle"><b>Day 36</b></entry></row></thead><tbody><row><entry align="center" valign="middle">I HFD</entry><entry align="center" valign="middle">37.25±5.0</entry><entry align="center" valign="middle">39.75±2.8 (4)</entry><entry align="center" valign="middle">27.5±6.3 (4)</entry><entry align="center" valign="middle">189.25 ± 18.0 (4)</entry></row><row><entry align="center" valign="middle">II 2(50 mg/kg)+HFD</entry><entry align="center" valign="middle">34.8±5.8 (7)</entry><entry align="center" valign="middle">37.57+2.8 (7)</entry><entry align="center" valign="middle">24.5±14.2 (7)</entry><entry align="center" valign="middle">123.87±14.0 (6)</entry></row><row><entry align="center" valign="middle">% Change</entry><entry align="center" valign="middle" /><entry align="center" valign="middle">181</entry><entry align="center" valign="middle" /><entry align="center" valign="middle">271</entry></row><row><entry align="center" valign="middle">III 2(100 mg/kg)+HFD</entry><entry align="center" valign="middle">43.4±8.3 (5)</entry><entry align="center" valign="middle">47.2±3.7 (5)</entry><entry align="center" valign="middle">10.02±8.5 (5)</entry><entry align="center" valign="middle">48.64±5.1 (5)</entry></row><row><entry align="center" valign="middle">% Change</entry><entry align="center" valign="middle" /><entry align="center" valign="middle">161</entry><entry align="center" valign="middle" /><entry align="center" valign="middle">741</entry></row></tbody></tgroup><tgroup cols="5" rowsep="0"><colspec colnum="1" colname="col1" colwidth="36mm" /><colspec colnum="2" colname="col2" colwidth="30mm" /><colspec colnum="3" colname="col3" colwidth="30mm" /><colspec colnum="4" colname="col4" colwidth="30mm" /><colspec colnum="5" colname="col5" colwidth="34mm" /><tbody><row><entry namest="col1" nameend="col5" align="justify"><i>HFD</i> = <i>High fat diet. Values are Mean SD. Figures in parenthesis are number of animals</i></entry></row></tbody></tgroup></table></tables></p>
    <heading id="h-00014-en">
      <b>5.1.4 Hypolipidemic Activity in Hyperlipidemic Rabbits</b>
    </heading>
    <p id="p-00031-en" num="0031">Effect of 3β-hydroxypregna-5,16-dien-20-one (<b>2</b>) was studied on hypercholesterolemic albino rabbits. Twelve male albino rabbits (approx 1.5-2 kg) on a stock diet were made hyperlipidemic by feeding daily cholesterol 0.5 g/kg in 2ml of groundnut oil for 45 days and then blood was drawn from the marginal vein in the ear of rabbits for serum cholesterol and triglycerides estimation.</p>
    <p id="p-00032-en" num="0032">Two controlled experiments were carried out for a period of three months. In one set of experiments, the control group received 0.5 g/kg of cholesterol for 90 days and 3β-hydroxypregna-5,16-dien-20-one (<b>2</b>) in dose of 100 mg/kg and 50 mg/kg while in the control group (given only cholesterol) a massive rise of serum cholesterol and triglycerides were seen after 90 days, the addition of 3β-hydroxypregna-5,16-dien-20-one (<b>2</b>) at 50 and 100mg/kg doses kept the rise well under control. The percentage decrease at 100mg dose was 28% at 30 days to 52% at 90 days for cholesterol and 45 to 81% for triglycerides. In the 50mg/kg dose group the decrease percentage ranged from 40% at 30 days to 50% at 90 days for cholesterol and 45% at 30 days to 75% at 90 days for triglyceride (Table-6) <tables id="tables-00006-en" num="0006"><table frame="all"><title><b>Table-6. Effect of 3β-Hdroxypregna-5,16-dien-20-one(2) in hyperlipidemic male-albino rabbits</b></title><tgroup cols="7"><colspec colnum="1" colname="col1" colwidth="50mm" /><colspec colnum="2" colname="col2" colwidth="19mm" /><colspec colnum="3" colname="col3" colwidth="19mm" /><colspec colnum="4" colname="col4" colwidth="21mm" /><colspec colnum="5" colname="col5" colwidth="19mm" /><colspec colnum="6" colname="col6" colwidth="19mm" /><colspec colnum="7" colname="col7" colwidth="19mm" /><thead><row><entry morerows="1" align="center" valign="middle"><b>Treatment</b></entry><entry namest="col2" nameend="col4" align="center" valign="middle"><b>S. Cholesterol (mg%) Days</b></entry><entry namest="col5" nameend="col7" align="center" valign="middle"><b>S.Triglycerides (mg%) Days</b></entry></row><row><entry align="center" valign="middle"><b>30</b></entry><entry align="center" valign="middle"><b>60</b></entry><entry align="center" valign="middle"><b>90</b></entry><entry align="center" valign="middle"><b>30</b></entry><entry align="center" valign="middle"><b>60</b></entry><entry align="center" valign="middle"><b>90</b></entry></row></thead><tbody><row><entry valign="middle">Expt. I.A Control +cholesterol(0.5g/kg)</entry><entry align="center" valign="middle">296.3</entry><entry align="center" valign="middle">435.5</entry><entry align="center" valign="middle">1337.5</entry><entry align="center" valign="middle">69.0</entry><entry align="center" valign="middle">150.0</entry><entry align="center" valign="middle">161.0</entry></row><row><entry valign="middle">Expt I.B 2(100mg/kg)+cholesterol(0.5/kg)</entry><entry align="center" valign="middle">213.3</entry><entry align="center" valign="middle">309.3</entry><entry align="center" valign="middle">633.7</entry><entry align="center" valign="middle">79.0</entry><entry align="center" valign="middle">54.0</entry><entry align="center" valign="middle">44.2</entry></row><row><entry valign="middle">% Decrease</entry><entry align="center" valign="middle"><b>28</b></entry><entry align="center" valign="middle"><b>42</b></entry><entry align="center" valign="middle"><b>53</b></entry><entry align="center" valign="middle"><b>46</b></entry><entry align="center" valign="middle"><b>64</b></entry><entry align="center" valign="middle"><b>81</b></entry></row><row><entry valign="middle">Expt II A Control -cholesterol(0.5g/kg)</entry><entry align="center" valign="middle">317.8</entry><entry align="center" valign="middle">531.8</entry><entry align="center" valign="middle">1334.6</entry><entry align="center" valign="middle">145.0</entry><entry align="center" valign="middle">185.8</entry><entry align="center" valign="middle">232.0</entry></row><row><entry valign="middle">Expt II B 2 (50 mg/kg)+ cholesterol (0.5g/kg)</entry><entry align="center" valign="middle">190.5</entry><entry align="center" valign="middle">305.5</entry><entry align="center" valign="middle">660.3</entry><entry align="center" valign="middle">79.5</entry><entry align="center" valign="middle">67.0</entry><entry align="center" valign="middle">56.5</entry></row><row><entry valign="middle">% Decrease</entry><entry align="center" valign="middle"><b>40</b></entry><entry align="center" valign="middle"><b>43</b></entry><entry align="center" valign="middle"><b>51</b></entry><entry align="center" valign="middle"><b>45</b></entry><entry align="center" valign="middle"><b>64</b></entry><entry align="center" valign="middle"><b>76</b></entry></row></tbody></tgroup></table></tables><tables id="tables-00007-en" num="0007"><table frame="all"><title><b>Table-7. Hypolipidemic effect in hyperlipidemic rabbits (120 days experiment)</b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="36mm" /><colspec colnum="2" colname="col2" colwidth="36mm" /><colspec colnum="3" colname="col3" colwidth="25mm" /><colspec colnum="4" colname="col4" colwidth="37mm" /><colspec colnum="5" colname="col5" colwidth="33mm" /><thead><row><entry align="center" valign="middle"><b>Parameters</b></entry><entry align="center" valign="middle"><b>Stock diet+ Normal saline</b></entry><entry align="center" valign="middle"><b>HFD</b></entry><entry align="center" valign="middle"><b>HFD+Guglip +2(100mg/kg)</b></entry><entry align="center" valign="middle"><b>HFD + 2 (100mg/kg)</b></entry></row></thead><tbody><row><entry valign="middle">Serum Cholesterol (mg/dl)</entry><entry align="center" valign="middle">56.3±3.1</entry><entry align="center" valign="middle">1367.0±203</entry><entry align="center" valign="middle">258.6±28.2</entry><entry align="center" valign="middle">350.0±28.1</entry></row><row><entry valign="middle">% Decrease (Compared with H FD)</entry><entry align="center" valign="middle" /><entry align="center" valign="middle" /><entry align="center" valign="middle"><b>81</b></entry><entry align="center" valign="middle"><b>74</b></entry></row><row><entry valign="middle">Serum Triglycerides</entry><entry align="center" valign="middle">50.0±2.1</entry><entry align="center" valign="middle">188.0±10.2</entry><entry align="center" valign="middle">66.2±4.1</entry><entry align="center" valign="middle">74.2±10.3</entry></row><row><entry valign="middle">% Decrease (Compared with HFD)</entry><entry align="center" valign="middle" /><entry align="center" valign="middle" /><entry align="center" valign="middle"><b>65</b></entry><entry align="center" valign="middle"><b>61</b></entry></row></tbody></tgroup></table></tables></p>
    <heading id="h-00015-en">
      <b>5.1.5 Hypolipidemic Activity in Rhesus Monkeys</b>
    </heading>
    <p id="p-00033-en" num="0033">In Rhesus monkeys: 3β-Hydroxypregna-5,16-dien-20-one (<b>2</b>) was administered orally daily for 90 days in doses of 62.5, 125 or 650 mg/kg to different group of animals. Significant decrease in serum cholesterol was observed (45-52%). At 90 days, percentage decrease in triglycerides varied from 14 to 36%. Compound <b>2</b> caused a marked decrease in low density lipoprotein (75-90%) whereas changes in HDL-cholesterol were not significant (Table-8 &amp; 9) <tables id="tables-00008-en" num="0008"><table frame="all"><title><b>Table-8</b>. <b>Effect of 3β-Hydroxypregna-5,16-dien-one (2) in Rhesus monkeys</b></title><tgroup cols="7"><colspec colnum="1" colname="col1" colwidth="47mm" /><colspec colnum="2" colname="col2" colwidth="22mm" /><colspec colnum="3" colname="col3" colwidth="19mm" /><colspec colnum="4" colname="col4" colwidth="14mm" /><colspec colnum="5" colname="col5" colwidth="20mm" /><colspec colnum="6" colname="col6" colwidth="19mm" /><colspec colnum="7" colname="col7" colwidth="14mm" /><thead><row><entry morerows="1" align="center" valign="middle"><b>Treatment</b></entry><entry namest="col2" nameend="col4" align="center" valign="middle"><b>S. Cholesterol Days</b></entry><entry namest="col5" nameend="col7" align="center" valign="middle"><b>S. Triglycerides Days</b></entry></row><row><entry align="center" valign="middle"><b>0</b></entry><entry align="center" valign="middle"><b>90</b></entry><entry align="center" valign="middle"><b>%Fall</b></entry><entry align="center" valign="middle"><b>0</b></entry><entry align="center" valign="middle"><b>60</b></entry><entry align="center" valign="middle"><b>% Fall</b></entry></row></thead><tbody><row><entry valign="middle">Expt. I Control +1% gum acacia</entry><entry align="center" valign="middle">119.8 ±16.6</entry><entry align="center" valign="middle">90.5 ±9.0</entry><entry align="center" valign="middle">26</entry><entry align="center" valign="middle">82.0 ±2.5</entry><entry align="center" valign="middle">62.0 ±1.0</entry><entry align="center" valign="middle">24</entry></row><row><entry valign="middle">Expt. II 2(62.5 mg/kg)</entry><entry align="center" valign="middle">156.8±23.0</entry><entry align="center" valign="middle">83.3 ±8.5</entry><entry align="center" valign="middle">47</entry><entry align="center" valign="middle">77.5 ±7.0</entry><entry align="center" valign="middle">66.3 ±6.9</entry><entry align="center" valign="middle">14</entry></row><row><entry valign="middle">Expt. III 2(125 mg/kg)</entry><entry align="center" valign="middle">133.3 ±8.5</entry><entry align="center" valign="middle">65.8±2.2</entry><entry align="center" valign="middle">50</entry><entry align="center" valign="middle">69.8 ±9.9</entry><entry align="center" valign="middle">60.0 ±2.9</entry><entry align="center" valign="middle">13</entry></row><row><entry valign="middle">Expt. IV 2(650 mg/kg)</entry><entry align="center" valign="middle">132.8 ±6.4</entry><entry align="center" valign="middle">63.3 ±2.3</entry><entry align="center" valign="middle">53</entry><entry align="center" valign="middle">90.5 ±3.9</entry><entry align="center" valign="middle">58.5±3.8</entry><entry align="center" valign="middle">36</entry></row></tbody></tgroup><tgroup cols="7" rowsep="0"><colspec colnum="1" colname="col1" colwidth="47mm" /><colspec colnum="2" colname="col2" colwidth="22mm" /><colspec colnum="3" colname="col3" colwidth="19mm" /><colspec colnum="4" colname="col4" colwidth="14mm" /><colspec colnum="5" colname="col5" colwidth="20mm" /><colspec colnum="6" colname="col6" colwidth="19mm" /><colspec colnum="7" colname="col7" colwidth="14mm" /><tbody><row><entry namest="col1" nameend="col7" align="justify"><i>Mean</i> ± <i>SD values mg</i>/<i>dl. Each set of experiment involved 4 monkeys</i></entry></row></tbody></tgroup></table></tables><tables id="tables-00009-en" num="0009"><table frame="all"><title><b>Table-9. Effect of β-Hydroxypregna-5,16-dien-20-one (2) on HDL- and LDL-cholesterol in Rhesus monkeys</b></title><tgroup cols="7"><colspec colnum="1" colname="col1" colwidth="31mm" /><colspec colnum="2" colname="col2" colwidth="24mm" /><colspec colnum="3" colname="col3" colwidth="24mm" /><colspec colnum="4" colname="col4" colwidth="22mm" /><colspec colnum="5" colname="col5" colwidth="26mm" /><colspec colnum="6" colname="col6" colwidth="24mm" /><colspec colnum="7" colname="col7" colwidth="17mm" /><thead><row><entry morerows="1" align="center" valign="middle"><b>Treatment</b></entry><entry namest="col2" nameend="col4" align="center" valign="middle"><b>HDL-Cholesterol</b> Days</entry><entry namest="col5" nameend="col7" align="center" valign="middle"><b>LDL-Cholesterol</b></entry></row><row><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">90</entry><entry align="center" valign="middle">% Change</entry><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">90</entry><entry align="center" valign="middle">% Fall</entry></row></thead><tbody><row><entry align="center" valign="middle">Expt. I Control +1% gum acacia</entry><entry align="center" valign="middle">45.5±7.4</entry><entry align="center" valign="middle">43.0±0.5</entry><entry align="center" valign="middle">-6</entry><entry align="center" valign="middle">57.9±16.2</entry><entry align="center" valign="middle">35.0±8.8</entry><entry align="center" valign="middle">39</entry></row><row><entry align="center" valign="middle">Expt. II 2(62.5 mg/kg)</entry><entry align="center" valign="middle">50.0±4.5</entry><entry align="center" valign="middle">45. ±2.5</entry><entry align="center" valign="middle">-8</entry><entry align="center" valign="middle">91.8±27.0</entry><entry align="center" valign="middle">24.3±8.0</entry><entry align="center" valign="middle">75</entry></row><row><entry align="center" valign="middle">Expt. III 2(125 mg/kg)</entry><entry align="center" valign="middle">46.3±2.0</entry><entry align="center" valign="middle">50.8±0.5</entry><entry align="center" valign="middle">+10</entry><entry align="center" valign="middle">63.5±7.4</entry><entry align="center" valign="middle">4.6±0.9</entry><entry align="center" valign="middle">90</entry></row><row><entry align="center" valign="middle">Expt.IV 2(650 mg/kg)</entry><entry align="center" valign="middle">39.3±1.3</entry><entry align="center" valign="middle">41.8±0.9</entry><entry align="center" valign="middle">+6</entry><entry align="center" valign="middle">72.7±8.4</entry><entry align="center" valign="middle">13.1±0.7</entry><entry align="center" valign="middle">82</entry></row></tbody></tgroup><tgroup cols="7" rowsep="0"><colspec colnum="1" colname="col1" colwidth="31mm" /><colspec colnum="2" colname="col2" colwidth="24mm" /><colspec colnum="3" colname="col3" colwidth="24mm" /><colspec colnum="4" colname="col4" colwidth="22mm" /><colspec colnum="5" colname="col5" colwidth="26mm" /><colspec colnum="6" colname="col6" colwidth="24mm" /><colspec colnum="7" colname="col7" colwidth="17mm" /><tbody><row><entry namest="col1" nameend="col7" align="justify"><i>Mean</i> ± <i>SD values mgldl.</i> Each set of experiment involved 4 monkeys.</entry></row></tbody></tgroup></table></tables></p>
    <heading id="h-00016-en">
      <b>5.2 Hypoglycemic Activity</b>
    </heading>
    <p id="p-00034-en" num="0034">The compounds were tested for their hypoglycemic effects in normal, glucose loaded and streptozotocin induced diabetic rats. The experimental details of the testing of one such compound 3β-hydroxypregna-5,16-dien-20-one (<b>2</b>) is described below which possessed marked hypoglycemic effect in two models. (Tables 10 and 11)</p>
    <heading id="h-00017-en">
      <b>5.2.1 Hypoglycemic Activity in Glucose Loaded Rats</b>
    </heading>
    <p id="p-00035-en" num="0035">The experiments were carried out with albino rats (Charles Foster strain) of either sex weighing 150-160 g. They were fed on laboratory diet prepared by M/s Lipton India Ltd. and maintained under 12 hr. light/dark cycle at 25±2°C.</p>
    <p id="p-00036-en" num="0036">The animals were divided into eight groups, each of six rats; group I was given 1% gum acacia (0.1ml/100g body weight) intragastrically (p.o.) and the group II were given 3β-hydroxypregna-5,16-dien-20-one (<b>2</b>) in 1% gum acacia, Animals of groups III were given the standard antidiabetic drug, tolbutamide in the similar fashion. 2.0g/kg glucose was given p.o. to all the rats along with the vehicle/Compound/Standard antidiabetic drug. Blood samples were taken from retroorbital plexus at periodic intervals. Glucose levels in the blood samples were measured by glucose oxidase method [<nplcit id="ncit-00037" npl-type="b"><text>Bergmeyer and Benut, 1963 cited in "Methods of Enzymatic Analysis" ed. H. Bergmeyer, Verlag Chemie, GmBH, Weinheim, Beroster, pp123, Academic press, New York</text></nplcit>].<tables id="tables-00010-en" num="0010"><table frame="all"><title><b>Table 10. Effect of 3β-Hydroxypregna-5,16-dien-20-one (2) and standard antidiabetic drug on post-prandial blood glucose level after challenge with glucose</b></title><tgroup cols="7"><colspec colnum="1" colname="col1" colwidth="23mm" /><colspec colnum="2" colname="col2" colwidth="24mm" /><colspec colnum="3" colname="col3" colwidth="24mm" /><colspec colnum="4" colname="col4" colwidth="24mm" /><colspec colnum="5" colname="col5" colwidth="25mm" /><colspec colnum="6" colname="col6" colwidth="25mm" /><colspec colnum="7" colname="col7" colwidth="24mm" /><thead><row><entry morerows="1" align="center" valign="top"><b>Group</b></entry><entry namest="col2" nameend="col6" align="center" valign="top"><b>Blood Glucose Level (mg/dl)</b></entry><entry morerows="1" valign="top"><b>Maximum Blood Glucose Change(%)</b></entry></row><row><entry align="center" valign="top"><b>0 min</b></entry><entry align="center" valign="top"><b>30 min</b></entry><entry align="center" valign="top"><b>60 min</b></entry><entry align="center" valign="top"><b>90 min</b></entry><entry align="center" valign="top"><b>120 min</b></entry></row></thead><tbody><row><entry>Control</entry><entry align="center">40.35±2.9</entry><entry align="center">102.3±6.11</entry><entry align="center">68.91 ±1.95</entry><entry align="center">66.48 ±2.12</entry><entry align="center">50.61 ±1.27</entry><entry align="center" /></row><row><entry>Compund 2 (100 mg/kg) + Glucose</entry><entry align="center">42.43±1.64</entry><entry align="center">76.15±6.07 (48)</entry><entry align="center">56.06±4.65 (55)</entry><entry align="center">55.06 ± 2.61 (54)</entry><entry align="center">49.59 ± 1.66 (34)</entry><entry align="char" char=".">-18.7</entry></row><row><entry>Tolbutamide (100 mg/kg) + Glucose</entry><entry align="center">38.15 ±2.02</entry><entry align="center">76.31 ±6.29 (35)</entry><entry align="center">27.26 ±3.1 (100)</entry><entry align="center">24.64 ± 1.92 (100)</entry><entry align="center">23.07 ±3.11 (100)</entry><entry align="char" char=".">-41.7</entry></row></tbody></tgroup><tgroup cols="7" rowsep="0"><colspec colnum="1" colname="col1" colwidth="23mm" /><colspec colnum="2" colname="col2" colwidth="24mm" /><colspec colnum="3" colname="col3" colwidth="24mm" /><colspec colnum="4" colname="col4" colwidth="24mm" /><colspec colnum="5" colname="col5" colwidth="25mm" /><colspec colnum="6" colname="col6" colwidth="25mm" /><colspec colnum="7" colname="col7" colwidth="24mm" /><tbody><row><entry namest="col1" nameend="col7" align="justify"><i>Figure in parenthesis indicates % inhibition compared to control</i> Mean ±SD values mg/dl. Each set of experiment involved 6 rats.</entry></row></tbody></tgroup></table></tables></p>
    <heading id="h-00018-en">
      <b>5.2.2 Hypoglycemic Activity in Streptozotocin Induced Hyperglycemic Rats</b>
    </heading>
    <p id="p-00037-en" num="0037">Hyperglycemia in rats was produced by streptozotocin treatment. The animals showing blood glucose levels between 250-350 mg/dl were selected. Blood samples were collected after treatment at intervals and blood glucose levels were estimated immediately. The results showed lowering in blood glucose level within 1 hr and the maximum fall was observed at 12 hrs.<tables id="tables-00011-en" num="0011"><table frame="all"><title><b>Table 11: Effect of 3β-Hydroxypregna-5, 16-dien-20-one (2) and Tolbutamide on blood glucose level of streptozotocin induced diabetic rats.</b></title><tgroup cols="11"><colspec colnum="1" colname="col1" colwidth="25mm" /><colspec colnum="2" colname="col2" colwidth="14mm" /><colspec colnum="3" colname="col3" colwidth="13mm" /><colspec colnum="4" colname="col4" colwidth="13mm" /><colspec colnum="5" colname="col5" colwidth="13mm" /><colspec colnum="6" colname="col6" colwidth="16mm" /><colspec colnum="7" colname="col7" colwidth="16mm" /><colspec colnum="8" colname="col8" colwidth="16mm" /><colspec colnum="9" colname="col9" colwidth="16mm" /><colspec colnum="10" colname="col10" colwidth="15mm" /><colspec colnum="11" colname="col11" colwidth="16mm" /><thead><row><entry morerows="1" valign="top"><b>Treatment</b></entry><entry namest="col2" nameend="col11" align="center" valign="top"><b>Blood glucose level mg/dl</b></entry></row><row><entry valign="top">0hr</entry><entry valign="top">1hr</entry><entry valign="top">2hr</entry><entry valign="top">3hr</entry><entry valign="top">4hr</entry><entry valign="top">5hr</entry><entry valign="top">6hr</entry><entry valign="top">7hr</entry><entry valign="top">8hr</entry><entry valign="top">24hr</entry></row></thead><tbody><row><entry>I Streptozotocin (50 mg/kg i.p.)</entry><entry>301 ± 7</entry><entry>314 ± 11</entry><entry>318 ± 12</entry><entry>328 ± 10</entry><entry>328 ± 15</entry><entry>333 ± 21</entry><entry>347 ± 19</entry><entry>355 ± 24</entry><entry>340 ± 22</entry><entry>349 ± 12</entry></row><row><entry>II Streptozotocin (50 mg/kg p.o.)<sup>+2</sup> (100 mg/kg p.o.)</entry><entry>274 ± 9</entry><entry>243* ± 10 (11.3)</entry><entry>231* ± 14 (15.6)</entry><entry>203** ± 20 (25.9)</entry><entry>183*** ±14 (33.2)</entry><entry>157*** ± 21 (42.7)</entry><entry>133*** ±16 (51.4)</entry><entry>102*** ± 9 (62.7)</entry><entry>91*** ± 8 (66.7)</entry><entry>128*** ± 18 (52.2)</entry></row><row><entry>IV Streptozotocin (50 mg/kg i.p. + Tolbutamide (100 mg/kg p.o.)</entry><entry>292 ± 10</entry><entry>218** ± 14 (25.3)</entry><entry>207** ± 17 (29.1)</entry><entry>202** ± 19 (30.8)</entry><entry>195** ±23 (33.2)</entry><entry>183** ± 23 (37.3)</entry><entry>174*** ± 23 (40.4)</entry><entry>192** ± 29 (34.2)</entry><entry>242* ± 18 (17.1)</entry><entry>332 ± 26</entry></row></tbody></tgroup><tgroup cols="11" rowsep="0"><colspec colnum="1" colname="col1" colwidth="25mm" /><colspec colnum="2" colname="col2" colwidth="14mm" /><colspec colnum="3" colname="col3" colwidth="13mm" /><colspec colnum="4" colname="col4" colwidth="13mm" /><colspec colnum="5" colname="col5" colwidth="13mm" /><colspec colnum="6" colname="col6" colwidth="16mm" /><colspec colnum="7" colname="col7" colwidth="16mm" /><colspec colnum="8" colname="col8" colwidth="16mm" /><colspec colnum="9" colname="col9" colwidth="16mm" /><colspec colnum="10" colname="col10" colwidth="15mm" /><colspec colnum="11" colname="col11" colwidth="16mm" /><tbody><row><entry namest="col1" nameend="col11" align="justify">Mean ± SD values mg/dl., Parenthesis shows % lowering from zero hour value.  *P&lt;0.05, **P&lt;0.01, ***P&lt;0.001</entry></row></tbody></tgroup></table></tables></p>
    <heading id="h-00019-en">
      <b>5.3. Antioxidant Activity:</b>
    </heading>
    <p id="p-00038-en" num="0038">The free radical oxidative stress has been implicated in the pathogenesis of a variety of human disease conditions including atherosclerosis. Polyunsaturated fatty acids within cell membranes and lipoproteins are oxidized and resulting active specie modify macrophages and bystander cells monocytes which then move to subendothelial space, engorge cholesteryl esters and are transformed into what are known as foam cells. Group of these foam cells form atherosclerotic plaques in the intima. The antioxidant potential of compound <b>2</b> was evaluated against metal induced oxidation of LDL as well as generation of hydroxy (OH) radical.</p>
    <p id="p-00039-en" num="0039">
      <i>In vivo</i> experiment with cholesterol fed animals caused marked formation of lipid peroxides in serum lipoproteins. Simultaneous treatment with compound <b>2</b> caused significant reversal of the lipid peroxide levels in serum VLDL, LDL and liver in cholesterol fed animals. However gemfibrozil failed to protect the phenomenon of lipid peroxidation (Table 12). Human serum LDL was oxidized with Cu<sup>+2</sup> in different concentrations of test compound in 0.05 mole PBS, pH7.4 for 16 hr at 37°C.</p>
    <p id="p-00040-en" num="0040">Thiobarbituric acid reactive lipid peroxides are measured by standard procedure. Compound 2 and α-tocopherol inhibit the generation of LDL lipid peroxide in concentration dependent manner. However the gemfibrozil at tested concentrations did not inhibit the oxidative modification (Table 13). Cu<sup>+2</sup> induced oxidation in LDL lipids are mainly due to the free OH radical during incubation. Therefore the effect tested for generation of OH radical <i>in vitro</i> in nonenzymatic system of Fe<sup>+2</sup>, sodium ascorbate, hydrogenperoxide and deoxyribose oxidative attack of oxy radical on deoxyribose caused fragmentation and formation of dialdehyde which are spectrophotometrically measured after their reaction with thiobarbituric acid. As observed in case of oxidation of LDL by metal ion, the compound 2 inhibits the generation of OH radical in concentration dependent manner. However, the activity of 2 is of low order to that of mannitol, a selective inhibitor of OH radical (Table 14) <tables id="tables-00012-en" num="0012"><table frame="all"><title><b>Table 12: Effect of 3β-Hydroxypregna-5,16-dien-20-one (2) on lipid peroxidation in cholesterol fed hyperlipidemic rats</b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="33mm" /><colspec colnum="2" colname="col2" colwidth="33mm" /><colspec colnum="3" colname="col3" colwidth="33mm" /><colspec colnum="4" colname="col4" colwidth="34mm" /><colspec colnum="5" colname="col5" colwidth="35mm" /><thead><row><entry morerows="1" valign="top">Serum/Tissue</entry><entry morerows="1" valign="top">Control</entry><entry morerows="1" valign="top">Cholesterol Fed</entry><entry namest="col4" nameend="col5" align="left" valign="top">Cholesterol + Drug (25 mg/kg)</entry></row><row><entry valign="top">Compound 2</entry><entry valign="top">Gemfibrozil</entry></row></thead><tbody><row><entry>Serum a</entry><entry>675 ± 82</entry><entry>1228 ±130 (+82)</entry><entry>931.5 ± 51 (-24)</entry><entry>1161 ± 74 (-5)</entry></row><row><entry>VLDL a</entry><entry>237 ± 25</entry><entry>379 ± 20 (+60)</entry><entry>310 ± 15 (-18)</entry><entry>346 ± 10 (-9)</entry></row><row><entry>LDL a</entry><entry>351 ± 17</entry><entry>604 ± 24 (+72)</entry><entry>421 ± 20 (-30)</entry><entry>568 ± 62 (-6)</entry></row><row><entry>HDL a</entry><entry>123 ± 13</entry><entry>138 ± 17 (+12)</entry><entry>125 ± 10 (-9)</entry><entry>134 ± 13 (-3)</entry></row><row><entry>Liver b</entry><entry>74 ± 8</entry><entry>274 ± 28 (+57)</entry><entry>212 ± 16 (-23)</entry><entry>253 ± 26 (-8)</entry></row></tbody></tgroup><tgroup cols="5" rowsep="0"><colspec colnum="1" colname="col1" colwidth="33mm" /><colspec colnum="2" colname="col2" colwidth="33mm" /><colspec colnum="3" colname="col3" colwidth="33mm" /><colspec colnum="4" colname="col4" colwidth="34mm" /><colspec colnum="5" colname="col5" colwidth="35mm" /><tbody><row><entry namest="col1" nameend="col5" align="justify">Values are mean ± SD of 6 rats; a=n mol MDA/dl, b=n mol MDA/g. Values in the parenthesis below drug treated groups are % reversal as compared with cholesterol fed rats.</entry></row></tbody></tgroup></table></tables><tables id="tables-00013-en" num="0013"><table frame="all"><title><b>Table 13: Effect of 3β-Hydroxy-pregna-5,16-dien-20-one (2), gemfibrozil and α-Tocopherol on low density lipoprotein oxidation.</b></title><tgroup cols="7"><colspec colnum="1" colname="col1" colwidth="24mm" /><colspec colnum="2" colname="col2" colwidth="23mm" /><colspec colnum="3" colname="col3" colwidth="25mm" /><colspec colnum="4" colname="col4" colwidth="24mm" /><colspec colnum="5" colname="col5" colwidth="24mm" /><colspec colnum="6" colname="col6" colwidth="23mm" /><colspec colnum="7" colname="col7" colwidth="25mm" /><thead><row rowsep="0"><entry valign="top">Concentration</entry><entry valign="top" /><entry valign="top">Compound 2</entry><entry valign="top">Gemifibrozil</entry><entry namest="col5" nameend="col7" align="center" valign="top">α-Tocopherol</entry></row><row><entry valign="top">(µmol/ml)</entry><entry valign="top" /><entry valign="top">MDA</entry><entry valign="top">MDA</entry><entry namest="col5" nameend="col6" align="left" valign="top">Conc. (µmol/ml)</entry><entry valign="top">MDA</entry></row></thead><tbody><row><entry>None</entry><entry /><entry>56.5 ± 3</entry><entry>52.0 ± 5.4</entry><entry>None</entry><entry /><entry>47.4 ± 3.8</entry></row><row><entry>2.5</entry><entry>Ref. Exp.</entry><entry>56.0 ± 5.8 41.4 ± 1.7 (26)</entry><entry>52.8 ± 5.7 53.0 ± 6.0 (-)</entry><entry>0.25</entry><entry>Ref. Exp.</entry><entry>47.4 ± 4.5 44.7 ± 4.5 (3)</entry></row><row><entry>5.0</entry><entry>Ref. Exp.</entry><entry>56.4 ± 5.6 28.7 ± 4.0 (49)</entry><entry>50.7 ± 6.1 48.8 ± 6.7 (5)</entry><entry>0.5</entry><entry>Ref. Exp.</entry><entry>47.3 ± 4.5 41.6 ± 4.0 (13)</entry></row><row><entry>10.0</entry><entry>Ref. Exp.</entry><entry>40.6 ± 3.7 10.6 ± 0.5 (74)</entry><entry>49.4 ± 5.2 43.8 ± 4.9</entry><entry>1.0</entry><entry>Ref. Exp.</entry><entry>47.4 ± 3.9 35.0 ± 3.8</entry></row><row><entry>20</entry><entry>Ref. Exp.</entry><entry>37.2 ± 0.8 4.0 ± 0.5 (89)</entry><entry>49.0 ± 2.9 41.4 ± 5.0 (16)</entry><entry>2.0</entry><entry>Ref Exp</entry><entry>47.4 ± 4.4 24.3 ± 2.0 (51)</entry></row></tbody></tgroup><tgroup cols="7" rowsep="0"><colspec colnum="1" colname="col1" colwidth="24mm" /><colspec colnum="2" colname="col2" colwidth="23mm" /><colspec colnum="3" colname="col3" colwidth="25mm" /><colspec colnum="4" colname="col4" colwidth="24mm" /><colspec colnum="5" colname="col5" colwidth="24mm" /><colspec colnum="6" colname="col6" colwidth="23mm" /><colspec colnum="7" colname="col7" colwidth="25mm" /><tbody><row><entry namest="col1" nameend="col7" align="justify">Values expressed as a mol MDA/mg protein are mean ± SD of four separate experiments Values in the parenthesis are % inhibition.</entry></row></tbody></tgroup></table></tables><tables id="tables-00014-en" num="0014"><table frame="all"><title><b>Table 14 Inhibition of Hydroxy (OH) radical formation in nonenzymatic system.</b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="29mm" /><colspec colnum="2" colname="col2" colwidth="27mm" /><colspec colnum="3" colname="col3" colwidth="25mm" /><colspec colnum="4" colname="col4" colwidth="28mm" /><colspec colnum="5" colname="col5" colwidth="26mm" /><thead><row rowsep="0"><entry valign="top">Concentration</entry><entry valign="top">Compound 2</entry><entry valign="top">Gemfibrozil</entry><entry namest="col4" nameend="col5" align="center" valign="top">α-Tocopherol</entry></row><row><entry valign="top">(µmol/ml)</entry><entry valign="top">(nmol MDA/hr)</entry><entry valign="top">(nmol MDA/hr)</entry><entry valign="top">Conc. (µmol/ml)</entry><entry valign="top">(nmol MDA/hr)</entry></row></thead><tbody><row><entry>None</entry><entry>90.4 ± 3.8</entry><entry>83.4 ± 7.5</entry><entry>None</entry><entry>78.2 ± 7.0</entry></row><row><entry>5</entry><entry>65.0 ± 5.4 (28)</entry><entry>79.9 ± 6.8 (4)</entry><entry>1</entry><entry>60.4 ± 7.0 (23)</entry></row><row><entry>10</entry><entry>52.8 ± 4.2 (42)</entry><entry>78.5 ± 8.0 (5)</entry><entry>2</entry><entry>45.2 ± 3.3 (42)</entry></row><row><entry>20</entry><entry>23.3 ± 1.8 (74)</entry><entry>76.8 ± 7.4 (8)</entry><entry>3</entry><entry>32.4 ± 3.5 (59)</entry></row><row><entry>30</entry><entry>11.7 ± 1.3 (87)</entry><entry>76.4 ± 3.8 (8)</entry><entry>4</entry><entry>27.1 ± 2.8 (65)</entry></row><row><entry>40</entry><entry>10.4 ± 2.0 (88)</entry><entry>74.3 ± 6.3 (II)</entry><entry>5</entry><entry>20.9 ± 2.0 (73)</entry></row><row><entry>50</entry><entry>9.9 ± 0.8 (90)</entry><entry>72.4 ± 8.0 (13)</entry><entry>-</entry><entry>-</entry></row></tbody></tgroup><tgroup cols="5" rowsep="0"><colspec colnum="1" colname="col1" colwidth="29mm" /><colspec colnum="2" colname="col2" colwidth="27mm" /><colspec colnum="3" colname="col3" colwidth="25mm" /><colspec colnum="4" colname="col4" colwidth="28mm" /><colspec colnum="5" colname="col5" colwidth="26mm" /><tbody><row><entry namest="col1" nameend="col5" align="justify">Values are mean ± SD of four separate observations.  Values in the parenthesis are % inhibition.</entry></row></tbody></tgroup></table></tables></p>
    <heading id="h-00020-en">5.4. Cardiac Protection:</heading>
    <p id="p-00041-en" num="0041">The underlying cause of myocardial infarction is believed to be the progressive deposition of lipids and fibrotic material into the arterial wall. These pregnadienols and pregnadienous also provided cardiac protection as assessed in isoproterneol induced myocardial necrosis in rat model, wich produces myocardial infarction due to an increased blood pressure and heart rate. The protection was comparable with that of gemfibrozil as described in Table 15<tables id="tables-00015-en" num="0015"><table frame="all"><title><b>Table 15: Effect of 3B-Hydroxypregna-5,16-dien-20-one(2) on serum and tissue parameters of heart necrosis at 25 mg/kg (p.o.) in rats.</b></title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="41mm" /><colspec colnum="2" colname="col2" colwidth="41mm" /><colspec colnum="3" colname="col3" colwidth="42mm" /><colspec colnum="4" colname="col4" colwidth="43mm" /><thead><row rowsep="0"><entry morerows="1" rowsep="1" valign="top">Parameters</entry><entry morerows="1" rowsep="1" align="center" valign="top">Isoproterneol (85 mg/kg, p.o.) % Change</entry><entry namest="col3" nameend="col4" align="center" valign="top">Isoproterneol + Drug (25 mg/kg) % Protection</entry></row><row><entry valign="top">Gemfibrozil</entry><entry valign="top">Compound 2</entry></row></thead><tbody><row><entry namest="col1" nameend="col4" align="left">Serum</entry></row><row><entry>CPK</entry><entry align="char" char=".">109.9 I</entry><entry align="char" char=".">33.9</entry><entry align="char" char="." charoff="9">35.7</entry></row><row><entry>GOT</entry><entry align="char" char=".">41.61</entry><entry align="char" char=".">24.9</entry><entry align="char" char="." charoff="9">27.0</entry></row><row><entry>GPT</entry><entry align="char" char=".">85.0 1</entry><entry align="char" char=".">33.4</entry><entry align="char" char="." charoff="9">22.7</entry></row><row><entry>Alkaline Phosphatase</entry><entry align="char" char=".">28.8 1</entry><entry align="char" char=".">41.2</entry><entry align="char" char="." charoff="9">24.0</entry></row><row><entry namest="col1" nameend="col4" align="left">Heart</entry></row><row><entry>Ga. - ATPase</entry><entry align="char" char=".">44.5 1</entry><entry align="char" char=".">30.2</entry><entry align="char" char="." charoff="9">30.2</entry></row><row><entry>Glycogen</entry><entry align="char" char=".">20.2 I</entry><entry align="char" char=".">32.1</entry><entry align="char" char="." charoff="9">25.1</entry></row><row><entry>Lipid peroxide</entry><entry align="char" char=".">65.8 I</entry><entry align="char" char=".">69.8</entry><entry align="char" char="." charoff="9">72.6</entry></row><row><entry>Phospholipase</entry><entry align="char" char=".">216.0 1</entry><entry align="char" char=".">28.2</entry><entry align="char" char="." charoff="9">74.2</entry></row></tbody></tgroup></table></tables></p>
    <heading id="h-00021-en">
      <b>5.5. ANDROGENIC ACTIVITY</b>
    </heading>
    <p id="p-00042-en" num="0042">The relative affinity of a few selected compounds in the series for cytoplasmic androgenic receptors present in human breast tumour cells MCF-7 ( Michigan Cancer Foundation, MCF, USA) was estimated and compared with 4,5-dihydrotestosterone (DHT). The results showed that the compounds 2,3 and 5 have no or only negligible binding affinity which therefore would be a reflection of their low androgenic effect.</p>
    <heading id="h-00022-en">
      <b>5.6. PROGESTATIONAL AND ANTIPROGESTATIONAL ACTIVITY</b>
    </heading>
    <p id="p-00043-en" num="0043">The relative affinity of compounds for cytoplasmic progesterone receptors present in human breast tumour cells (MCF-7) were estimated and compared with 16-ethyl-21-hydroxy-19-norpregna-4-ene-3,20-dione (Org 2058). The experiments conducted revealed that the compounds 2,3 and 5 have no or only negligible binding affinity.</p>
    <p id="p-00044-en" num="0044">The progestational activity was also tested <i>in vivo</i> by Clauberg assay method. The degree of endometrial proliferation was estimated on the McPhail scale where 3' or 4' was considered as a full progestational effect 3β-Hydroxypregna-5,16-dien-20-one (<b>2</b>) did not exhibit any activity even at 200 mg/kg dose, whereas progesterone showed, as expected marked progestational activity even at 50 mg/kg.</p>
  </description>
  <claims id="claims_eng" lang="eng" format="original" date-changed="20081224">
    <claim num="1" id="clm-00001-en" independent="true">
      <claim-text>Use of a compound selected from the group consisting of 3β-hydroxypregna-5,16-dien-20-one, 4,16-dienpregna-3, 20-dione, 3β-hydroxypregna-5-en-20-one, 5,16-dien-pregnane-3, 20-diol and 5,17(20)-dienpregna-3,16-diol, in the manufacture of a medicament for the treatment or prophylaxis of a hyperlipidemic and/or hyperglycemic condition.</claim-text>
    </claim>
    <claim num="2" id="clm-00002-en">
      <claim-text>Use of a compound as claimed in claim 1, in the manufacture of a medicament for the treatment or prophylaxis of a diabetic condition.</claim-text>
    </claim>
    <claim num="3" id="clm-00003-en">
      <claim-text>Use of a compound as claimed in claim 1, in the manufacture of a medicament for lowering serum cholesterol, triglyceride and/or glucose levels in a subject with obesity or a diabetic condition.</claim-text>
    </claim>
    <claim num="4" id="clm-00004-en">
      <claim-text>Use as claimed in any of claims 1 to 3, wherein the compound is 3β-hydroxy-pregna-5,16-dien-20-one.</claim-text>
    </claim>
    <claim num="5" id="clm-00005-en">
      <claim-text>Use as claimed in any of claims 1 to 4, wherein the compound is optionally administered as an admixture with one or more other therapeutic agents selected from anti-platelet aggregation, anti-artherosclerotic, hypolipoproteinic and antidiabetic drugs.</claim-text>
    </claim>
    <claim num="6" id="clm-00006-en">
      <claim-text>Use as claimed in any of claims 1 to 5 wherein the medicament is in the form of a tablet, capsule or injectible.</claim-text>
    </claim>
    <claim num="7" id="clm-00007-en" independent="true">
      <claim-text>A compound selected from the group consisting of 3β-hydroxypregna-5,16-dien-20-one, 4,16-dienpregna-3,20-dione, 3β-hydroxypregna-5-en-20-one, 5,16-dien-pregnane-3,20-diol and 5,17(20)-Dienpregna-3,16-diol for use in the treatment of a hyperlipidemic and/or hyperglycemic condition.</claim-text>
    </claim>
  </claims>
  <claims id="claims_fre" lang="fre" format="original" date-changed="20081224">
    <claim num="1" id="clm-00001-fr" independent="true">
      <claim-text>Utilisation d'un composé choisi dans le groupe constitué de 3β-hydroxypregna-5,16-dién-20-one, 4,16-dienpregna-3, 20-dione, 3β-hydroxypregna-5-én-20-one, 5,16-dien-pregnane-3, 20-diol et 5,17(20)-dienpregna-3,16-diol, dans la fabrication d'un médicament pour le traitement ou la prophylaxie d'un état hyperlipidémique et/ou hyperglycémique.</claim-text>
    </claim>
    <claim num="2" id="clm-00002-fr">
      <claim-text>Utilisation d'un composé selon la revendication 1, dans la fabrication d'un médicament pour le traitement ou la prophylaxie d'un état diabétique.</claim-text>
    </claim>
    <claim num="3" id="clm-00003-fr">
      <claim-text>Utilisation d'un composé selon la revendication 1, dans la fabrication d'un médicament pour abaisser les taux sériques en cholestérol, triglycéride et/ou glucose chez un sujet souffrant d'obésité ou d'un état diabétique.</claim-text>
    </claim>
    <claim num="4" id="clm-00004-fr">
      <claim-text>Utilisation selon l'une quelconque des revendications 1 à 3, dans laquelle le composé est du 3β-hydroxy-pregna-5,16-dién-20-one.</claim-text>
    </claim>
    <claim num="5" id="clm-00005-fr">
      <claim-text>Utilisation selon l'une quelconque des revendications 1 à 4, dans laquelle le composé est facultativement administré en tant que mélange avec un ou plusieurs autres agents thérapeutiques choisi(s) parmi les médicaments anti-agrégation plaquettaire, anti-arthérosclérotiques, hypolipoprotéiniques et antidiabétiques.</claim-text>
    </claim>
    <claim num="6" id="clm-00006-fr">
      <claim-text>Utilisation selon l'une quelconque des revendications 1 à 5, dans laquelle le médicament est sous la forme d'une tablette, d'une gélule ou injectable.</claim-text>
    </claim>
    <claim num="7" id="clm-00007-fr" independent="true">
      <claim-text>Composé choisi dans le groupe constitué de 3β-hydroxypregna-5,16-dién-20-one, 4,16-dienpregna-3,20-dione, 3β-hydroxypregna-5-én-20-one, 5,16-dién-pregnane-3,20-diol et 5,17(20)-Dienpregna-3,16-dioI pour une utilisation dans le traitement d'un état hyperlipidémique et/ou hyperglycémique.</claim-text>
    </claim>
  </claims>
  <claims id="claims_ger" lang="ger" format="original" date-changed="20081224">
    <claim num="1" id="clm-00001-de" independent="true">
      <claim-text>Verwendung einer Verbindung ausgewählt aus der Gruppe bestehend aus 3β-Hydroxypregna-5,16-dien-20-on, 4,16-Dienpregna-3,20-Dion, 3β-Hydroxypregna-5-en-20-on, 5,16-Dien-pregnan-3,20-Diol und 5,17(20)-Dienpregna-3,16-Diol bei der Herstellung eines Medikaments zur Behandlung oder Prophylaxe eines hyperlipidämischen und/oder hyperglykämischen Zustands.</claim-text>
    </claim>
    <claim num="2" id="clm-00002-de">
      <claim-text>Verwendung einer Verbindung nach Anspruch 1 bei der Herstellung eines Medikaments zur Behandlung oder Prophylaxe eines diabetischen Zustands.</claim-text>
    </claim>
    <claim num="3" id="clm-00003-de">
      <claim-text>Verwendung einer Verbindung nach Anspruch 1 bei der Herstellung eines Medikaments zum Senken der/des Serum-Cholesterin-, Triglycerid- und/oder Glucosespiegel/s bei einem Subjekt, das an Fettsucht oder einem diabetischen Zustand leidet.</claim-text>
    </claim>
    <claim num="4" id="clm-00004-de">
      <claim-text>Verwendung nach einem der Ansprüche 1 bis 3, wobei die Verbindung 3β-Hydroxy-pregna-5,16-dien-20-on ist.</claim-text>
    </claim>
    <claim num="5" id="clm-00005-de">
      <claim-text>Verwendung nach einem der Ansprüche 1 bis 4, wobei die Verbindung gegebenenfalls als eine Mischung mit einem oder mehreren anderen therapeutischen Mittel/n ausgewählt aus der Gruppe von Medikamenten gegen Plättchenaggregation, Arteriosklerose, Diabetes und Hypolipoprotein-Medikamenten verabreicht wird.</claim-text>
    </claim>
    <claim num="6" id="clm-00006-de">
      <claim-text>Verwendung nach einem der Ansprüche 1 bis 5, wobei das Medikament in der Form einer Tablette oder Kapsel vorliegt oder injizierbar ist.</claim-text>
    </claim>
    <claim num="7" id="clm-00007-de" independent="true">
      <claim-text>Verbindung ausgewählt aus der Gruppe bestehend aus 3β-Hydroxypregna-5,16-dien-20-on, 4,16-Dienpregna-3,20-Dion, 3β-Hydroxypregna-5-en-20-on, 5,16-Dien-pregnan-3,20-Diol und 5,17(20)-Dienpregna-3,16-Diol zur Verwendung bei der Behandlung eines hyperlipidämischen und/oder hyperglykämischen Zustands.</claim-text>
    </claim>
  </claims>
  <drawings>
    <figure num="1">
      <img he="N/A" wi="N/A" file="EP1020191B1_00001.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="2">
      <img he="N/A" wi="N/A" file="EP1020191B1_00002.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="3">
      <img he="N/A" wi="N/A" file="EP1020191B1_00003.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="4">
      <img he="N/A" wi="N/A" file="EP1020191B1_00004.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="5">
      <img he="N/A" wi="N/A" file="EP1020191B1_00005.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="6">
      <img he="N/A" wi="N/A" file="EP1020191B1_00006.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="7">
      <img he="N/A" wi="N/A" file="EP1020191B1_00007.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="8">
      <img he="N/A" wi="N/A" file="EP1020191B1_00008.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="9">
      <img he="N/A" wi="N/A" file="EP1020191B1_00009.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="10">
      <img he="N/A" wi="N/A" file="EP1020191B1_00010.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="11">
      <img he="N/A" wi="N/A" file="EP1020191B1_00011.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="12">
      <img he="N/A" wi="N/A" file="EP1020191B1_00012.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
  </drawings>
  <image file="EP1020191B1.PDF" type="pdf" size="148395" pages="18" />
</lexisnexis-patent-document>